Search
Cisplatin Treatment Options in United Kingdom
A collection of 298 research studies where Cisplatin is the interventional treatment. These studies are located in the United Kingdom . Cisplatin is used for conditions such as Head and Neck Cancer, Lung Cancer and Non-Small Cell Lung Cancer.
97 - 108 of 298
Show Filters
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Male
Female
Both
Type of Study
Interventional
Observational
Clinical Trial Phase
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
Unknown
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Recruiting
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib. Read Less
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
01/09/2025
Locations: Research Site, La Jolla, California +284 locations
Research Site, La Jolla, California
Research Site, Orange City, Florida
Research Site, Orlando, Florida
Research Site, Honolulu, Hawaii
Research Site, Evergreen Park, Illinois
Research Site, Boston, Massachusetts
Research Site, Boston, Massachusetts
Research Site, Detroit, Michigan
Research Site, Florham Park, New Jersey
Research Site, New Brunswick, New Jersey
Research Site, New York, New York
Research Site, Canton, Ohio
Research Site, Nashville, Tennessee
Research Site, Berazategui, Not set
Research Site, Buenos Aires, Not set
Research Site, Caba, Not set
Research Site, Cordoba, Not set
Research Site, Florida, Not set
Research Site, La Rioja, Not set
Research Site, Rosario, Not set
Research Site, Rosario, Not set
Research Site, San Miguel de Tucumán, Not set
Research Site, Viedma, Not set
Research Site, Clayton, Not set
Research Site, Fremantle, Not set
Research Site, Geelong, Not set
Research Site, Liverpool, Not set
Research Site, Southport, Not set
Research Site, Waratah NSW, Not set
Research Site, Westmead, Not set
Research Site, Graz, Not set
Research Site, Salzburg, Not set
Research Site, Wien, Not set
Research Site, Bruxelles, Not set
Research Site, Bruxelles, Not set
Research Site, Edegem, Not set
Research Site, Gent, Not set
Research Site, Hasselt, Not set
Research Site, Mons, Not set
Research Site, Roeselare, Not set
Research Site, Sint-Niklaas, Not set
Research Site, Belo Horizonte, Not set
Research Site, Brasilia, Not set
Research Site, Cachoeiro de Itapemirim, Not set
Research Site, Curitiba, Not set
Research Site, Ijuí, Not set
Research Site, Ipatinga, Not set
Research Site, Porto Alegre, Not set
Research Site, Porto Alegre, Not set
Research Site, Porto Alegre, Not set
Research Site, Rio De Janeiro, Not set
Research Site, Rio De Janeiro, Not set
Research Site, Salvador, Not set
Research Site, Salvador, Not set
Research Site, São Paulo, Not set
Research Site, São Paulo, Not set
Research Site, São Paulo, Not set
Research Site, Vitória, Not set
Research Site, Haskovo, Not set
Research Site, Pleven, Not set
Research Site, Plovdiv, Not set
Research Site, Sofia, Not set
Research Site, Varna, Not set
Research Site, Vratsa, Not set
Research Site, Calgary, Alberta
Research Site, Mississauga, Ontario
Research Site, Toronto, Ontario
Research Site, Toronto, Ontario
Research Site, Montreal, Quebec
Research Site, Montreal, Quebec
Research Site, Santiago, Not set
Research Site, Santiago, Not set
Research Site, Temuco, Not set
Research Site, Baoding, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Bengbu, Not set
Research Site, Changchun, Not set
Research Site, Changsha, Not set
Research Site, Changsha, Not set
Research Site, Changsha, Not set
Research Site, Chengdu, Not set
Research Site, Chongqing, Not set
Research Site, Fuzhou, Not set
Research Site, Fuzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Hankou,Wuhan, Not set
Research Site, Harbin, Not set
Research Site, Hefei, Not set
Research Site, Jinan, Not set
Research Site, Linyi, Not set
Research Site, Nanchang, Not set
Research Site, Qingdao, Not set
Research Site, Shanghai, Not set
Research Site, Shenyang, Not set
Research Site, Shenzhen, Not set
Research Site, Wuhan, Not set
Research Site, Xi'an, Not set
Research Site, Xiangfan, Not set
Research Site, Xian, Not set
Research Site, Yichang, Not set
Research Site, Zhengzhou, Not set
Research Site, Angers, Not set
Research Site, Bobigny, Not set
Research Site, Bordeaux Cedex, Not set
Research Site, Brest, Not set
Research Site, Creteil, Not set
Research Site, Dijon, Not set
Research Site, Marseille, Not set
Research Site, Montpellier, Not set
Research Site, Paris, Not set
Research Site, Paris, Not set
Research Site, Poitiers, Not set
Research Site, Rennes, Not set
Research Site, Rouen, Not set
Research Site, Saint-Herblain, Not set
Research Site, Saint-Quentin, Not set
Research Site, Strasbourg Cedex, Not set
Research Site, Suresnes Cedex, Not set
Research Site, Berlin, Not set
Research Site, Berlin, Not set
Research Site, Chemnitz, Not set
Research Site, Frankfurt A. Main, Not set
Research Site, Gauting, Not set
Research Site, Homburg, Not set
Research Site, Immenhausen, Not set
Research Site, Löwenstein, Not set
Research Site, Muenster, Not set
Research Site, München, Not set
Research Site, Stuttgart, Not set
Research Site, Wangen, Not set
Research Site, Athens, Not set
Research Site, Athens, Not set
Research Site, Chaidari, Not set
Research Site, Heraklion, Not set
Research Site, Larissa, Not set
Research Site, Rio, Not set
Research Site, Thessaloniki, Not set
Research Site, Thessaloniki, Not set
Research Site, HKG, Not set
Research Site, Hong Kong, Not set
Research Site, Kowloon, Not set
Research Site, Afula, Not set
Research Site, Ashdod, Not set
Research Site, Be'er Ya'akov, Not set
Research Site, Hadera, Not set
Research Site, Jerusalem, Not set
Research Site, Tel Aviv, Not set
Research Site, Avellino, Not set
Research Site, Aviano, Not set
Research Site, Catania, Not set
Research Site, Meldola, Not set
Research Site, Milano, Not set
Research Site, Milan, Not set
Research Site, Modena, Not set
Research Site, Monserrato, Not set
Research Site, Napoli, Not set
Research Site, Orbassano, Not set
Research Site, Padova, Not set
Research Site, Parma, Not set
Research Site, Perugia, Not set
Research Site, Peschiera Del Garda, Not set
Research Site, Roma, Not set
Research Site, Roma, Not set
Research Site, Treviso, Not set
Research Site, Bunkyo-ku, Not set
Research Site, Chuo-ku, Not set
Research Site, Fukuoka-shi, Not set
Research Site, Hirosaki-shi, Not set
Research Site, Hiroshima-shi, Not set
Research Site, Iwakuni-shi, Not set
Research Site, Kanazawa-shi, Not set
Research Site, Kashiwa, Not set
Research Site, Kobe-shi, Not set
Research Site, Kobe, Not set
Research Site, Kumamoto-shi, Not set
Research Site, Kurume-shi, Not set
Research Site, Matsuyama, Not set
Research Site, Nagasaki-shi, Not set
Research Site, Okayama-shi, Not set
Research Site, Osaka-shi, Not set
Research Site, Osakasayama-shi, Not set
Research Site, Sakai-shi, Not set
Research Site, Sapporo-shi, Not set
Research Site, Sapporo-shi, Not set
Research Site, Sendai-shi, Not set
Research Site, Sunto-gun, Not set
Research Site, Utsunomiya-shi, Not set
Research Site, Wakayama-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Goyang-si, Not set
Research Site, Gyeonggi-do, Not set
Research Site, Incheon, Not set
Research Site, Jinju-si, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Suwon, Not set
Research Site, Ulsan, Not set
Research Site, Kota Bharu, Not set
Research Site, Kuala Lumpur, Not set
Research Site, Petaling Jaya, Not set
Research Site, Pulau Pinang, Not set
Research Site, Sabah, Not set
Research Site, Amsterdam, Not set
Research Site, Bacolod, Not set
Research Site, Baguio City, Not set
Research Site, Cebu City, Not set
Research Site, Cebu, Not set
Research Site, Davao City, Not set
Research Site, Manila, Not set
Research Site, Quezon City, Not set
Research Site, Quezon City, Not set
Research Site, Quezon City, Not set
Research Site, San Juan, Not set
Research Site, Bialystok, Not set
Research Site, Krakow, Not set
Research Site, Olsztyn, Not set
Research Site, Łódź, Not set
Research Site, Chelyabinsk, Not set
Research Site, Moscow, Not set
Research Site, Saint Petersburg, Not set
Research Site, Tomsk, Not set
Research Site, Singapore, Not set
Research Site, Singapore, Not set
Research Site, Badajoz, Not set
Research Site, Badalona, Not set
Research Site, Barcelona, Not set
Research Site, Barcelona, Not set
Research Site, Cordoba, Not set
Research Site, Girona, Not set
Research Site, La Coruña, Not set
Research Site, Madrid, Not set
Research Site, Madrid, Not set
Research Site, Madrid, Not set
Research Site, Majadahonda, Not set
Research Site, Málaga, Not set
Research Site, Pontevedra, Not set
Research Site, Sabadell, Not set
Research Site, Sevilla, Not set
Research Site, Valencia, Not set
Research Site, Zaragoza, Not set
Research Site, Baden, Not set
Research Site, Basel, Not set
Research Site, Bern, Not set
Research Site, Winterthur, Not set
Research Site, Zürich, Not set
Research Site, Chiayi, Not set
Research Site, Hsinchu, Not set
Research Site, Kaohsiung City, Not set
Research Site, Liuying, Not set
Research Site, Taichung, Not set
Research Site, Taichung, Not set
Research Site, Taipei 112, Not set
Research Site, Taipei City, Not set
Research Site, Taipei, Not set
Research Site, Bangkok, Not set
Research Site, Bangkok, Not set
Research Site, Chiang Mai, Not set
Research Site, Dusit, Not set
Research Site, Hat Yai, Not set
Research Site, Muang, Not set
Research Site, Mueang Chanthaburi, Not set
Research Site, Adana, Not set
Research Site, Ankara, Not set
Research Site, Edirne, Not set
Research Site, Istanbul, Not set
Research Site, Istanbul, Not set
Research Site, Izmir, Not set
Research Site, Bristol, Not set
Research Site, Leicester, Not set
Research Site, Liverpool, Not set
Research Site, London, Not set
Research Site, Manchester, Not set
Research Site, Newport, Not set
Research Site, Reading, Not set
Research Site, Wolverhampton, Not set
Research Site, Can Tho, Not set
Research Site, Hanoi City, Not set
Research Site, Hanoi, Not set
Research Site, Hanoi, Not set
Research Site, Ho Chi Minh city, Not set
Research Site, Ho Chi Minh, Not set
Conditions: Carcinoma, Non-Small-Cell Lung
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Active Not Recruiting
This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned after a period of improvement or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from d... Read More
This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned after a period of improvement or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as filgrastim or pegfilgrastim, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. It is not yet known whether high-dose combination chemotherapy and stem cell transplant are more effective than standard-dose combination chemotherapy in treating patients with refractory or relapsed germ cell tumors. Read Less
Gender:
MALE
Ages:
14 years and above
Trial Updated:
01/09/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +124 locations
Children's Hospital of Alabama, Birmingham, Alabama
UC San Diego Moores Cancer Center, La Jolla, California
Loma Linda University Medical Center, Loma Linda, California
USC / Norris Comprehensive Cancer Center, Los Angeles, California
Kaiser Permanente-Oakland, Oakland, California
Stanford Cancer Institute Palo Alto, Palo Alto, California
UCSF Medical Center-Mission Bay, San Francisco, California
Alfred I duPont Hospital for Children, Wilmington, Delaware
MedStar Georgetown University Hospital, Washington, District of Columbia
University of Florida Health Science Center - Gainesville, Gainesville, Florida
Nemours Children's Clinic-Jacksonville, Jacksonville, Florida
Nicklaus Children's Hospital, Miami, Florida
Miami Cancer Institute, Miami, Florida
Arnold Palmer Hospital for Children, Orlando, Florida
Johns Hopkins All Children's Hospital, Saint Petersburg, Florida
Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Northwestern University, Chicago, Illinois
Rush University Medical Center, Chicago, Illinois
University of Illinois, Chicago, Illinois
University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Ascension Via Christi Hospitals Wichita, Wichita, Kansas
Cancer Center of Kansas - Wichita, Wichita, Kansas
Ochsner Medical Center Jefferson, New Orleans, Louisiana
Dana-Farber Cancer Institute, Boston, Massachusetts
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Spectrum Health at Butterworth Campus, Grand Rapids, Michigan
University of Michigan Health - West, Wyoming, Michigan
Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota
Mayo Clinic in Rochester, Rochester, Minnesota
Washington University School of Medicine, Saint Louis, Missouri
Nebraska Methodist Hospital, Omaha, Nebraska
Summerlin Hospital Medical Center, Las Vegas, Nevada
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
Hackensack University Medical Center, Hackensack, New Jersey
Memorial Sloan Kettering Monmouth, Middletown, New Jersey
Saint Joseph's Regional Medical Center, Paterson, New Jersey
Roswell Park Cancer Institute, Buffalo, New York
Memorial Sloan Kettering Commack, Commack, New York
Memorial Sloan Kettering Cancer Center, New York, New York
Memorial Sloan Kettering Nassau, Uniondale, New York
Memorial Sloan Kettering Westchester, West Harrison, New York
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Ohio State University Comprehensive Cancer Center, Columbus, Ohio
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Rhode Island Hospital, Providence, Rhode Island
Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina
Medical University of South Carolina, Charleston, South Carolina
Prisma Health Cancer Institute - Easley, Easley, South Carolina
Saint Francis Hospital, Greenville, South Carolina
BI-LO Charities Children's Cancer Center, Greenville, South Carolina
Prisma Health Cancer Institute - Butternut, Greenville, South Carolina
Prisma Health Cancer Institute - Faris, Greenville, South Carolina
Prisma Health Greenville Memorial Hospital, Greenville, South Carolina
Saint Francis Cancer Center, Greenville, South Carolina
Prisma Health Cancer Institute - Eastside, Greenville, South Carolina
Prisma Health Cancer Institute - Greer, Greer, South Carolina
Prisma Health Cancer Institute - Seneca, Seneca, South Carolina
Spartanburg Medical Center, Spartanburg, South Carolina
Saint Jude Children's Research Hospital, Memphis, Tennessee
The Children's Hospital at TriStar Centennial, Nashville, Tennessee
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
El Paso Children's Hospital, El Paso, Texas
M D Anderson Cancer Center, Houston, Texas
Seattle Children's Hospital, Seattle, Washington
Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin
Marshfield Medical Center-Marshfield, Marshfield, Wisconsin
Medical College of Wisconsin, Milwaukee, Wisconsin
Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin
Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin
Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin
Marshfield Medical Center - Weston, Weston, Wisconsin
Royal Prince Alfred Hospital, Camperdown, New South Wales
Princess Alexandra Hospital, Woolloongabba, Queensland
Box Hill Hospital, Box Hill, Victoria
Peter MacCallum Cancer Centre, Melbourne, Victoria
Institut Jules Bordet, Anderlecht, Not set
University Hospital Saint Luc, Brussels, Not set
Rigshospitalet University Hospital, Copenhagen, Not set
Centre Leon Berard, Lyon, Not set
Institut Paoli Calmettes, Marseille, Not set
Hopital Tenon/Assistance Publique - Hopitaux de Paris, Paris, Not set
CHRU Strasbourg - Hospital Civil, Strasbourg, Not set
Center Claudius Regaud, Toulouse, Not set
Centre Alexis Vautrin, Vandoeuvre-les-Nancy, Not set
Gustave Roussy, Villejuif, Not set
Technical University Dresden, Dresden, Saxony
University of Berlin Charite Campus Benjamin Franklin, Berlin, Not set
University of Dusseldorf, Dusseldorf, Not set
University of Essen, Essen, Not set
University Medical Center Hamburg-Eppendorf, Hamburg, Not set
UniversitaetsKlinikum Heidelberg, Heidelberg, Not set
GK-Mittelrhein Saint Martin's, Koblenz, Not set
Philipps University Marburg, Marburg, Not set
Rotkreuzklinikum Munchen, Munich, Not set
Klinikum Nurnberg Nord, Nurnberg, Not set
University Hospital Ulm, Ulm, Not set
Saint James Hospital, Dublin, Not set
Ospedale di Circolo di Busto Arsizio, Busto Arsizio, Not set
Istituto Scientifico Romagnolo, Meldola, Not set
Istituto Nazionale Tumori, Milano, Not set
San Matteo Hospital, Pavia, Not set
The Netherlands Cancer Institute, Amsterdam, Not set
University Medical Center Groningen, Groningen, Not set
Radboud University Nijmegen Medical Centre, Nijmegen, Not set
Hospital De La Santa Creu I Sant Pau, Barcelona, Not set
Duran i Reynals Hospital-Catalan Institute of Oncology, Barcelona, Not set
Hospital Universitario 12 de Octubre, Madrid, Not set
Hospital General Universitario Morales Meseguer, Murcia, Not set
Inselspital, Bern, Not set
Hopitaux Universitaires de Geneve, Geneva, Not set
University Hospital Zurich, Zurich, Not set
Saint Bartholomew's Hospital, London, England
Christie Hospital, Manchester, England
Weston Park Hospital, Sheffield, England
Southampton General Hospital, Southampton, England
Saint James's University Hospital, West Yorkshire, England
Beatson Oncology Center, Glasgow, Scotland
Nottingham City Hospital, Nottingham, Not set
The Royal Marsden NHS Foundation Trust - Sutton, Surrey, Not set
Conditions: Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Completed
To compare the efficacy and safety of ceritinib with standard first-line chemotherapy (pemetrexed plus cisplatin or carboplatin) in patients with stage IIIB (not candidates for definitive multimodality therapy) or stage IV, non-squamous non-small cell lung cancer (NSCLC) harboring a confirmed anaplastic lymphoma kinase (ALK) rearrangement, using the Ventana immunohistochemistry (IHC) test.
To compare the efficacy and safety of ceritinib with standard first-line chemotherapy (pemetrexed plus cisplatin or carboplatin) in patients with stage IIIB (not candidates for definitive multimodality therapy) or stage IV, non-squamous non-small cell lung cancer (NSCLC) harboring a confirmed anaplastic lymphoma kinase (ALK) rearrangement, using the Ventana immunohistochemistry (IHC) test. Read Less
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
12/20/2024
Locations: Novartis Investigative Site, Caba, Buenos Aires +166 locations
Novartis Investigative Site, Caba, Buenos Aires
Novartis Investigative Site, Caba, Buenos Aires
Novartis Investigative Site, La Rioja, Not set
Novartis Investigative Site, Woolloongabba, Queensland
Novartis Investigative Site, Heidelberg, Victoria
Novartis Investigative Site, Auckland, Not set
Novartis Investigative Site, Salzburg, Not set
Novartis Investigative Site, Wien, Not set
Novartis Investigative Site, Salvador, BA
Novartis Investigative Site, Fortaleza, CE
Novartis Investigative Site, Recife, PE
Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul
Novartis Investigative Site, Rio De Janiero, RJ
Novartis Investigative Site, Natal, RN
Novartis Investigative Site, Itajai, SC
Novartis Investigative Site, Barretos, SP
Novartis Investigative Site, Sao Jose do Rio Preto, SP
Novartis Investigative Site, Sao Paulo, SP
Novartis Investigative Site, Guangzhou, Guangdong
Novartis Investigative Site, Chang Chun, Jilin
Novartis Investigative Site, Changchun, Jilin
Novartis Investigative Site, Shanghai, Shanghai
Novartis Investigative Site, XI An, Shanxi
Novartis Investigative Site, Chengdu, Sichuan
Novartis Investigative Site, Hangzhou, Zhejiang
Novartis Investigative Site, Hangzhou, Zhejiang
Novartis Investigative Site, Beijing, Not set
Novartis Investigative Site, Beijing, Not set
Novartis Investigative Site, Chongqing, Not set
Novartis Investigative Site, Chongqing, Not set
Novartis Investigative Site, Guang Dong Province, Not set
Novartis Investigative Site, Tianjin, Not set
Novartis Investigative Site, Bogota, Cundinamarca
Novartis Investigative Site, Monteria, Not set
Novartis Investigative Site, Herlev, Not set
Novartis Investigative Site, Odense C, Not set
Novartis Investigative Site, Limoges, Haute Vienne
Novartis Investigative Site, Toulon Cedex 9, Val De Marne
Novartis Investigative Site, Caen, Not set
Novartis Investigative Site, Grenoble, Not set
Novartis Investigative Site, Lille, Not set
Novartis Investigative Site, Paris 10, Not set
Novartis Investigative Site, Pierre Benite, Not set
Novartis Investigative Site, Rennes, Not set
Novartis Investigative Site, Strasbourg Cedex, Not set
Novartis Investigative Site, Villejuif, Not set
Novartis Investigative Site, Coswig, Not set
Novartis Investigative Site, Essen, Not set
Novartis Investigative Site, Gottingen, Not set
Novartis Investigative Site, Grosshansdorf, Not set
Novartis Investigative Site, Heidelberg, Not set
Novartis Investigative Site, Koeln, Not set
Novartis Investigative Site, Oldenburg, Not set
Novartis Investigative Site, Tuebingen, Not set
Novartis Investigative Site, Ulm, Not set
Novartis Investigative Site, Wiesbaden, Not set
Novartis Investigative Site, Athens, GR
Novartis Investigative Site, Heraklion Crete, Not set
Novartis Investigative Site, Zalaegerszeg, Zala
Novartis Investigative Site, Budapest, Not set
Novartis Investigative Site, Nyiregyhaza, Not set
Novartis Investigative Site, Veszprem, Not set
Novartis Investigative Site, Hyderabad, Andhra Pradesh
Novartis Investigative Site, New Delhi, Delhi
Novartis Investigative Site, Bangalore, Karnataka
Novartis Investigative Site, Kochi, Kerala
Novartis Investigative Site, Nashik, Maharashtra
Novartis Investigative Site, Jaipur, Rajasthan
Novartis Investigative Site, Vellore, Tamil Nadu
Novartis Investigative Site, Madurai, TamilNadu
Novartis Investigative Site, Kolkata, West Bengal
Novartis Investigative Site, Delhi, Not set
Novartis Investigative Site, Mumbai, Not set
Novartis Investigative Site, Dublin 4, Not set
Novartis Investigative Site, Ancona, AN
Novartis Investigative Site, Bergamo, BG
Novartis Investigative Site, Genova, GE
Novartis Investigative Site, Monza, MB
Novartis Investigative Site, Milano, MI
Novartis Investigative Site, Milano, MI
Novartis Investigative Site, Milano, MI
Novartis Investigative Site, Rozzano, MI
Novartis Investigative Site, Perugia, PG
Novartis Investigative Site, Pisa, PI
Novartis Investigative Site, Aviano, PN
Novartis Investigative Site, Parma, PR
Novartis Investigative Site, Reggio Emilia, RE
Novartis Investigative Site, Roma, RM
Novartis Investigative Site, Roma, RM
Novartis Investigative Site, Orbassano, TO
Novartis Investigative Site, Udine, UD
Novartis Investigative Site, Napoli, Not set
Novartis Investigative Site, Nagoya, Aichi
Novartis Investigative Site, Kashiwa, Chiba
Novartis Investigative Site, Akashi, Hyogo
Novartis Investigative Site, Hirakata-city, Osaka
Novartis Investigative Site, Osaka-city, Osaka
Novartis Investigative Site, Koto ku, Tokyo
Novartis Investigative Site, Niigata, Not set
Novartis Investigative Site, Bundang Gu, Gyeonggi Do
Novartis Investigative Site, Gyeonggi do, Korea
Novartis Investigative Site, Seoul, Not set
Novartis Investigative Site, Seoul, Not set
Novartis Investigative Site, Seoul, Not set
Novartis Investigative Site, Ashrafieh, Not set
Novartis Investigative Site, Saida, Not set
Novartis Investigative Site, Guadalajara, Jalisco
Novartis Investigative Site, Leiden, Zuid Holland
Novartis Investigative Site, Amersfroort, Not set
Novartis Investigative Site, Enschede, Not set
Novartis Investigative Site, Groningen, Not set
Novartis Investigative Site, Groningen, Not set
Novartis Investigative Site, Maastricht, Not set
Novartis Investigative Site, Zoetermeer, Not set
Novartis Investigative Site, Oslo, Not set
Novartis Investigative Site, Szczecin, Not set
Novartis Investigative Site, Warszawa, Not set
Novartis Investigative Site, Moscow, Not set
Novartis Investigative Site, Saint Petersburg, Not set
Novartis Investigative Site, Singapore, Not set
Novartis Investigative Site, Singapore, Not set
Novartis Investigative Site, Granada, Andalucia
Novartis Investigative Site, Malaga, Andalucia
Novartis Investigative Site, Sevilla, Andalucia
Novartis Investigative Site, Sevilla, Andalucia
Novartis Investigative Site, Oviedo, Asturias
Novartis Investigative Site, Lerida, Cataluna
Novartis Investigative Site, Mataro, Cataluna
Novartis Investigative Site, Reus, Cataluna
Novartis Investigative Site, Barcelona, Catalunya
Novartis Investigative Site, Barcelona, Catalunya
Novartis Investigative Site, Hospitalet de LLobregat, Catalunya
Novartis Investigative Site, Alicante, Comunidad Valenciana
Novartis Investigative Site, Valencia, Comunidad Valenciana
Novartis Investigative Site, Badajoz, Extremadura
Novartis Investigative Site, La Coruna, Galicia
Novartis Investigative Site, Lugo, Galicia
Novartis Investigative Site, Palma De Mallorca, Islas Baleares
Novartis Investigative Site, Pamplona, Navarra
Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife
Novartis Investigative Site, Barcelona, Not set
Novartis Investigative Site, Madrid, Not set
Novartis Investigative Site, Madrid, Not set
Novartis Investigative Site, Madrid, Not set
Novartis Investigative Site, Madrid, Not set
Novartis Investigative Site, Linkoping, Not set
Novartis Investigative Site, Lund, Not set
Novartis Investigative Site, Stockholm, Not set
Novartis Investigative Site, Uppsala, Not set
Novartis Investigative Site, Kaohsiung, Not set
Novartis Investigative Site, Taichung, Not set
Novartis Investigative Site, Taichung, Not set
Novartis Investigative Site, Taipei, Not set
Novartis Investigative Site, Taipei, Not set
Novartis Investigative Site, Taoyuan, Not set
Novartis Investigative Site, Songkhla, Hat Yai
Novartis Investigative Site, Khon Kaen, THA
Novartis Investigative Site, Bangkok, Not set
Novartis Investigative Site, Bangkok, Not set
Novartis Investigative Site, Ankara, Not set
Novartis Investigative Site, Istanbul, Not set
Novartis Investigative Site, Exeter, Devon
Novartis Investigative Site, Leeds, West Yorkshire
Novartis Investigative Site, Birmingham, Not set
Novartis Investigative Site, London, Not set
Novartis Investigative Site, Manchester, Not set
Novartis Investigative Site, Nottingham, Not set
Conditions: Non-Small Cell Lung Cancer
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
Active Not Recruiting
The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy \[gemcitabine plus cisplatin\] and RC + PLND) for participants with MIBC who are cisplatin-eligible. The primary hypothesis is perioperative EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS)... Read More
The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy \[gemcitabine plus cisplatin\] and RC + PLND) for participants with MIBC who are cisplatin-eligible. The primary hypothesis is perioperative EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS) compared with neoadjuvant gemcitabine + cisplatin and RC + PLND (Arm B). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Mayo Clinic in Arizona - Phoenix ( Site 0043), Phoenix, Arizona +187 locations
Mayo Clinic in Arizona - Phoenix ( Site 0043), Phoenix, Arizona
St Joseph Heritage Healthcare-Oncology ( Site 0035), Fullerton, California
UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro, Los Angeles, California
University of California San Francisco ( Site 0010), San Francisco, California
Stanford University ( Site 0023), Stanford, California
University of Colorado, Anschutz Cancer Pavilion ( Site 0009), Aurora, Colorado
UF Health ( Site 0031), Gainesville, Florida
Indiana University Melvin and Bren Simon Cancer Center ( Site 0050), Indianapolis, Indiana
University of Iowa Hospital and Clinics ( Site 0029), Iowa City, Iowa
University of Louisville, James Graham Brown Cancer Center ( Site 0022), Louisville, Kentucky
Icahn School of Medicine at Mount Sinai ( Site 0011), New York, New York
White Plains Hospital ( Site 0039), White Plains, New York
Duke University Medical Center ( Site 0017), Durham, North Carolina
Wake Forest Baptist Health ( Site 0014), Winston-Salem, North Carolina
Oregon Health and Science University ( Site 0028), Portland, Oregon
MidLantic Urology ( Site 0002), Bala-Cynwyd, Pennsylvania
Saint Francis Cancer Center ( Site 0008), Greenville, South Carolina
The University of Tennessee Medical Center ( Site 0034), Knoxville, Tennessee
UT Southwestern Medical Center ( Site 0003), Dallas, Texas
Houston Methodist Urology Associates ( Site 0033), Houston, Texas
Urology of San Antonio ( Site 0020), San Antonio, Texas
University of Wisconsin Hospital and Clinics ( Site 0037), Madison, Wisconsin
Hospital Británico de Buenos Aires-Oncology ( Site 1551), Ciudad autónoma de Buenos Aires, Buenos Aires
Hospital Italiano de Buenos Aires ( Site 1554), ABB, Caba
Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 1558), Buenos Aires, Caba
Fundacion Estudios Clinicos-Oncology ( Site 1557), Rosario, Santa Fe
Centro de Urología (CDU) ( Site 1552), Buenos Aires, Not set
Asociación de Beneficencia Hospital Sirio Libanés ( Site 1553), Buenos Aires, Not set
Macquarie University-MQ Health Clinical Trials Unit ( Site 1259), Macquarie University, New South Wales
Mater Hospital Brisbane ( Site 1257), South Brisbane, Queensland
Lyell McEwin Hospital ( Site 1252), Elizabeth Vale, South Australia
Frankston Hospital-Oncology and Haematology ( Site 1258), Frankston, Victoria
MHAT "Uni Hospital" OOD ( Site 1154), Panagyurishte, Pazardzhik
Complex Oncology Center Plovdiv ( Site 1151), Plovdiv, Not set
MHAT Central Onco Hospital OOD ( Site 1158), Plovdiv, Not set
MHAT Serdika ( Site 1152), Sofia, Not set
BC Cancer - Vancouver Center ( Site 0110), Vancouver, British Columbia
CancerCare Manitoba ( Site 0108), Winnipeg, Manitoba
Moncton Hospital ( Site 0107), Moncton, New Brunswick
Ottawa Hospital Research Institute ( Site 0109), Ottawa, Ontario
Jewish General Hospital ( Site 0106), Montreal, Quebec
SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 1406), Guangzhou, Guangdong
Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 1413), Guangzhou, Guangdong
Hunan Cancer Hospital ( Site 1403), Changsha, Hunan
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S, Nanjing, Jiangsu
Nantong Tumor Hospital-Urology ( Site 1405), Nantong, Jiangsu
Fudan University Shanghai Cancer Center-Urology department ( Site 1401), Shanghai, Shanghai
Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 1402), Shanghai, Shanghai
Fundación Colombiana de Cancerología Clínica Vida ( Site 1653), Medellin, Antioquia
Oncomédica S.A.S ( Site 1652), Montería, Cordoba
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 1654), Bogota, Distrito Capital De Bogota
Fundación Cardiovascular de Colombia-Santander ( Site 1657), Piedecuesta, Santander
Fundacion Valle del Lili- CIC ( Site 1656), Cali, Valle Del Cauca
Klinički bolnički centar Sestre milosrdnice ( Site 1703), Zagreb, Grad Zagreb
Klinički bolnički centar Zagreb-Klinika za onkologiju ( Site 1701), Zagreb, Grad Zagreb
Klinički bolnički centar Osijek ( Site 1705), Osijek, Osjecko-baranjska Zupanija
Klinički Bolnički Centar Split-Oncology and Radiotherapy ( Site 1702), Split, Splitsko-dalmatinska Zupanija
Fakultni nemocnice u sv. Anny v Brne ( Site 0253), Brno, Jihomoravsky Kraj
Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 0254), Hradec Kralove, Not set
Fakultni Nemocnice Olomouc ( Site 0251), Olomouc, Not set
Fakultni Thomayerova nemocnice ( Site 0252), Praha 4, Not set
CHU La Timone ( Site 0456), Marseille, Bouches-du-Rhone
CHU Jean Minjoz ( Site 0453), Besancon, Doubs
CHU de Brest -Site Hopital Morvan ( Site 0461), Brest, Finistere
Institut Universitaire du Cancer Toulouse - Oncopole ( Site 0455), Toulouse, Haute-Garonne
CHU Limoges Hopital Dupuytren ( Site 0459), Limoges, Haute-Vienne
Gustave Roussy ( Site 0467), Villejuif, Ile-de-France
CHU GRENOBLE ALPES ( Site 0468), La Tronche, Isere
Centre Hospitalier Regional du Orleans ( Site 0463), Orleans, Loiret
Polyclinique du Bois ( Site 0458), Lille, Nord
Hopital Diaconesses Croix Saint Simon ( Site 0465), Paris, Not set
Universitaetsklinikum Freiburg ( Site 0512), Freiburg, Baden-Wurttemberg
Universitaetsklinik fuer Urologie ( Site 0501), Tuebingen, Baden-Wurttemberg
Caritas Krankenhaus St. Josef ( Site 0502), Regensburg, Bayern
Universitaetsklinikum Wuerzburg ( Site 0520), Wuerzburg, Bayern
Kath. Krankenhaus Marienhospital. Universitaetsklinik ( Site 0511), Herne, Nordrhein-Westfalen
Universitaetsklinikum Muenster ( Site 0516), Muenster, Nordrhein-Westfalen
Krankenhaus Martha Maria Halle-Doelau ( Site 0507), Halle, Sachsen-Anhalt
Universitaetsklinikum Carl Gustav Carus ( Site 0509), Dresden, Sachsen
Vivantes Klinikum Am Urban ( Site 0519), Berlin, Not set
UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 0305), Patras, Achaia
General Hospital of Athens "Alexandra" ( Site 0303), Athens, Attiki
Athens Medical Center ( Site 0304), Athens, Attiki
ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 0301), Chaidari, Attiki
University General Hospital of Larissa ( Site 0302), Larissa, Thessalia
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ ( Site 1010), Szeged, Csongrad
Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 1002), Szolnok, Jasz-Nagykun-Szolnok
Debreceni Egyetem Klinikai Kozpont ( Site 1006), Debrecen, Not set
Rambam Health Care Campus-Oncology ( Site 0751), Haifa, Not set
Hadassah Medical Center-Oncology ( Site 0757), Jerusalem, Not set
Meir Medical Center-oncology ( Site 0754), Kfar Saba, Not set
Rabin Medical Center-Oncology ( Site 0752), Petah-Tikva, Not set
Sheba Medical Center-ONCOLOGY ( Site 0753), Ramat Gan, Not set
Sourasky Medical Center-Oncology ( Site 0755), Tel Aviv, Not set
Yitzhak Shamir Medical Center-Oncology ( Site 0756), Zerifin, Not set
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0588), Milan, Lombardia
Presidio Ospedaliero Santa Maria delle Grazie ( Site 0599), Pozzuoli, Napoli
AOU San Luigi Gonzaga di Orbassano ( Site 0595), Orbassano, Torino
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento ( Site 0598), Verona, Veneto
Azienda Ospedaliero Universitaria delle Marche-Clinica Oncologica ( Site 0593), Ancona, Not set
Ospedale Cannizzaro ( Site 0590), Catania, Not set
IRCCS Ospedale San Raffaele ( Site 0596), Milano, Not set
Istituto Oncologico Veneto IRCCS-Oncologia Medica 1 ( Site 0600), Padova, Not set
Nagoya University Hospital ( Site 1512), Nagoya, Aichi
Hirosaki University Hospital ( Site 1501), Hirosaki, Aomori
University of Tsukuba Hospital ( Site 1502), Tsukuba, Ibaraki
Kanazawa University Hospital ( Site 1509), Kanazawa, Ishikawa
Kitasato University Hospital ( Site 1506), Sagamihara, Kanagawa
Yokohama City University Medical Center ( Site 1508), Yokohama, Kanagawa
Kanagawa Cancer Center ( Site 1507), Yokohama, Kanagawa
Tohoku University Hospital ( Site 1503), Sendai, Miyagi
Hamamatsu University Hospital ( Site 1511), Hamamatsu, Shizuoka
Gifu University Hospital ( Site 1513), Gifu, Not set
Nagasaki University Hospital ( Site 1517), Nagasaki, Not set
Okayama University Hospital ( Site 1516), Okayama, Not set
Osaka International Cancer Institute ( Site 1514), Osaka, Not set
Osaka Metropolitan University Hospital ( Site 1515), Osaka, Not set
Tokyo Medical and Dental University Hospital ( Site 1505), Tokyo, Not set
Keio University Hospital ( Site 1504), Tokyo, Not set
Toyama University Hospital ( Site 1510), Toyama, Not set
Chonnam National University Hwasun Hospital ( Site 1353), Jeollanam-do, Jeonranamdo
Seoul National University Bundang Hospital ( Site 1355), Gyeonggi-do, Kyonggi-do
Asan Medical Center ( Site 1352), Songpagu, Seoul
Kyungpook National University Chilgok Hospital ( Site 1354), Daegu, Taegu-Kwangyokshi
Gachon University Gil Medical Center ( Site 1356), Incheon, Not set
Korea University Anam Hospital ( Site 1357), Seoul, Not set
Seoul National University Hospital ( Site 1351), Seoul, Not set
University Malaya Medical Centre ( Site 0352), Lembah Pantai, Kuala Lumpur
Hospital Pulau Pinang ( Site 0355), George Town, Pulau Pinang
Sarawak General Hospital ( Site 0351), Kuching, Sarawak
Sunway Medical Centre ( Site 0353), Petaling Jaya, Selangor
THE MEDICAL CITY ILOILO-The Medical City Iloilo - Clinical and Translational Research Institute-Ilo, Iloilo City, Iloilo
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu ( Site 1058), Wrocław, Dolnoslaskie
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1057), Siedlce, Mazowieckie
Narodowy Instytut Onkologii ( Site 1051), Warszawa, Mazowieckie
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1053), Przemysl, Podkarpackie
Clinical Research Center Medic-R ( Site 1061), Poznan, Wielkopolskie
Szpital Wojewodzki im. Mikolaja Kopernika ( Site 1055), Koszalin, Zachodniopomorskie
Centro Hospitalar e Universitario de Coimbra ( Site 0406), Coimbra, Not set
Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE ( Site 0409), Lisboa, Not set
CHLO, EPE - Hospital de Sao Francisco Xavier ( Site 0401), Lisboa, Not set
Hospital Geral de Santo Antonio ( Site 0408), Porto, Not set
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1102), Cluj Napoca, Cluj
Cardiomed SRL Cluj-Napoca ( Site 1101), Cluj-Napoca, Cluj
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1103), Cluj-Napoca, Cluj
SC Radiotherapy Center Cluj SRL ( Site 1108), Comuna Floresti, Cluj
S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1107), Craiova, Dolj
Policlinica Oncomed SRL ( Site 1106), Timisoara, Timis
SC Focus Lab Plus SRL ( Site 1104), Bucuresti, Not set
Institutul Oncologic Cluj-Oncologie Medicala ( Site 1109), Cluj, Not set
Altay Regional Oncology Dispensary ( Site 0851), Barnaul, Altayskiy Kray
National Medical Research Radiology Centre ( Site 0869), Obninsk, Kaluzskaja Oblast
National Medical Research Centre of Oncology named after N.N. Blokhin ( Site 0865), Moscow, Moskva
First Moscow State Medical University n.a. I.M.Sechenov ( Site 0871), Moscow, Moskva
Volga District Medical Center ( Site 0876), Nizhny Novgorod, Nizhegorodskaya Oblast
St.Petersburg Clinical Hospital RAS ( Site 0864), Saint Petersburg, Sankt-Peterburg
St.Petersburg State Medical Univ. n.a. acad. I.P.Pavlov ( Site 0856), Saint Petersburg, Sankt-Peterburg
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0852), Saint Petersburg, Sankt-Peterburg
Sverdlovsk Regional Oncology Hospital ( Site 0867), Ekaterinburg, Sverdlovskaya Oblast
Sverdlovsky Regional Clinical hospital #1 ( Site 0868), Ekaterinburg, Sverdlovskaya Oblast
Volgograd Regional Uronephrological Center ( Site 0870), Volzhsky, Volgogradskaya Oblast
Tan Tock Seng Hospital ( Site 0704), Singapore, Central Singapore
Wits Clinical Research ( Site 0603), Johannesburg, Gauteng
Steve Biko Academic Hospital ( Site 0601), Pretoria, Gauteng
Groote Schuur Hospital ( Site 0602), Cape Town, Western Cape
Hospital Universitario Central de Asturias ( Site 0654), Oviedo, Asturias
Hospital Germans Trias i Pujol. ICO de Badalona ( Site 0658), Badalona, Barcelona
Xarxa Assistencial Universitaria Manresa ( Site 0655), Manresa, Barcelona
Institut Català d'Oncologia (ICO) - Girona ( Site 0653), Girona, Gerona
CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 0660), Santiago de Compostela, La Coruna
Hospital Universitario Insular de Gran Canaria ( Site 0657), Las Palmas de Gran Canaria, Las Palmas
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 0662), Valencia, Valenciana, Comunitat
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0661), Barcelona, Not set
Hospital Clinico Universitario San Carlos de Madrid ( Site 0651), Madrid, Not set
Hospital Virgen del Rocio ( Site 0659), Sevilla, Not set
Chang Gung Memorial Hospital at Kaohsiung ( Site 1203), Kaohsiung Niao Sung Dist, Kaohsiung
China Medical University Hospital ( Site 1202), Taichung, Not set
Taipei Veterans General Hospital ( Site 1201), Taipei, Not set
I.I. Mechnykov Dnipropetrovsk Regional Clinical Hospital ( Site 0959), Dnipro, Dnipropetrovska Oblast
MI Clinical oncology dispensary of Dnipropetrovsk regional council ( Site 0954), Dnipro, Dnipropetrovska Oblast
Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval ( Site 0952), Kharkiv, Kharkivska Oblast
MNPE Regional Center of Oncology ( Site 0955), Kharkiv, Kharkivska Oblast
Municipal Non-profit Enterprise of Kharkiv Regional Council RCSDRPP ( Site 0965), Kharkiv, Kharkivska Oblast
Lviv Oncology Regional Treatment and Diagnostic Center ( Site 0960), Lviv, Lvivska Oblast
Zhytomyr Regional Oncology Center ( Site 0961), Zhytomyr, Zhytomyrska Oblast
Torbay Hospital ( Site 1804), Torquay, Devon
St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 1801), London, London, City Of
Imperial College Healthcare NHS Foundation Trust - St Mary's Hospital ( Site 1802), London, London, City Of
Conditions: Bladder Cancer
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Recruiting
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5). Read Less
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
12/09/2024
Locations: HonorHealth Research Institute, Scottsdale, Arizona +33 locations
HonorHealth Research Institute, Scottsdale, Arizona
Precision NextGen Oncology and Research, Beverly Hills, California
City of Hope, Duarte, California
Valkyrie Clinical Trials, Los Angeles, California
University of California, San Diego (UCSD) - Moores Cancer Center, San Diego, California
University of California, San Francisco (UCSF), San Francisco, California
Sarcoma Oncology Center, Santa Monica, California
University of Colorado Hospital, Aurora, Colorado
Emory University - Winship Cancer Institute, Atlanta, Georgia
The University of Chicago, Chicago, Illinois
Center for Cancer Research at NCI, Bethesda, Maryland
University of Michigan, Ann Arbor, Michigan
START Midwest Michigan, PC, Grand Rapids, Michigan
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York
Cleveland Clinic, Cleveland, Ohio
Oregon Health & Science University, Portland, Oregon
Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia, Pennsylvania
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
Vanderbilt University School of Medicine, Nashville, Tennessee
UT MD Anderson Cancer Center, Houston, Texas
NEXT Oncology, San Antonio, Texas
University of Virginia, Charlottesville, Virginia
NEXT Oncology - Virginia, Fairfax, Virginia
Centre Leon Berard, Lyon, Not set
Gustave Roussy, Villejuif Cedex, Not set
La Fondazione e l'Istituto di Candiolo, Candiolo, Not set
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Not set
Hospital Universitario Vall d'Hebron, Barcelona, Not set
Hospital de la Santa Creu i Sant Pau, Barcelona, Not set
Hospital Clinico San Carlos, Madrid, Not set
Great North Children's Hospital, London, Not set
University College London Hospital, London, Not set
The Royal Marsden NHS Foundation Trust, London, Not set
Royal Manchester Children's Hospital, Manchester, Not set
Conditions: Colorectal Adenocarcinoma, Ewing Sarcoma
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
Completed
The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease
The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Memorial Health Systems, Colorado Springs, Colorado +115 locations
Memorial Health Systems, Colorado Springs, Colorado
Local Institution - 0044, Plainville, Connecticut
Local Institution - 0045, Jacksonville, Florida
Local Institution - 0029, Marietta, Georgia
Local Institution - 0091, Wichita, Kansas
Local Institution - 0004, Lexington, Kentucky
Local Institution - 0105, Detroit, Michigan
Local Institution - 0058, Johnson City, New York
Local Institution - 0098, Mineola, New York
Local Institution - 0095, Columbus, Ohio
Local Institution - 0006, Lancaster, Pennsylvania
Local Institution - 0047, Pittsburgh, Pennsylvania
Local Institution - 0093, Pittsburgh, Pennsylvania
Local Institution - 0094, Charleston, South Carolina
Southwest Regional Cancer Clinic, Saint George, Utah
Local Institution - 0099, Madison, Wisconsin
Local Institution - 0014, Ciudad Autónoma de Buenos Aires, Buenos Aires
Local Institution - 0028, Rio Cuarto, Cordoba
Local Institution - 0026, Viedma, Rio Negro
Local Institution - 0027, Rosario, Santa Fe
Local Institution - 0030, Cordoba, Not set
Local Institution - 0086, Gosford, New South Wales
Local Institution - 0040, Bedford Park, South Australia
Local Institution - 0089, Box Hill, Victoria
Local Institution - 0036, Heidelberg, Victoria
Local Institution - 0078, Murdoch, Western Australia
Local Institution - 0002, Gilly, Not set
Local Institution - 0033, Leuven, Not set
Local Institution - 0001, Roeselare, Not set
Local Institution - 0068, Natal, RIO Grande DO Norte
Local Institution - 0063, Ijui, Rio Grande Do Sul
Local Institution - 0067, Porto Alegre, Rio Grande Do Sul
Local Institution - 0069, Blumenau, Santa Catarina
Local Institution - 0064, Barretos, Sao Paulo
Local Institution - 0065, Sao Jose Do Rio Preto, Sao Paulo
Local Institution - 0066, Rio De Janeiro, Not set
Local Institution - 0070, São Paulo, Not set
Local Institution - 0090, Montreal, Quebec
Local Institution - 0083, Montreal, Quebec
Local Institution - 0082, Montreal, Quebec
Local Institution - 0080, Rimouski, Quebec
Local Institution - 0084, Santiago, Metropolitana
Local Institution - 0059, Santiago, Región Metropolitana De Santiago
Local Institution - 0079, Vina Del Mar, Valparaiso
Local Institution - 0139, Beijing, BEI
Local Institution - 0146, Haikou, Hainan
Local Institution - 0148, Zhengzhou, Henan
Local Institution - 0120, Zhengzhou, Henan
Local Institution - 0144, Changsha, Hunan
Local Institution - 0106, Changchun, Jilin
Local Institution - 0108, Xi'an City, Shan3xi
Local Institution - 0110, Hangzhou, Zhejiang
Local Institution - 0111, Zhejiang, Zhejiang
Local Institution - 0113, Beijing, Not set
Local Institution - 0112, Shanghai, Not set
Local Institution - 0010, Bron, Rhone Alpes
Local Institution - 0009, Lyon Cedex08, Rhône-Alpes
Local Institution - 0013, Caen, Not set
Local Institution - 0071, Lille Cedex, Not set
Local Institution - 0012, Montpellier, Not set
Local Institution - 0035, Nantes, Not set
Local Institution - 0011, Paris Cedex 20, Not set
Local Institution - 0097, Saint-Brieuc, Not set
Local Institution - 0073, Berlin, Not set
Local Institution - 0016, Gauting, Not set
Local Institution - 0072, Grosshansdorf, Not set
Local Institution - 0019, Hemer, Not set
Local Institution - 0017, Immenhausen, Not set
Local Institution - 0074, Magdeburg, Not set
Local Institution - 0015, Muenchen, Not set
Local Institution - 0018, Stuttgart, Not set
Local Institution - 0021, Dublin, Not set
Local Institution - 0020, Limerick, Not set
Local Institution - 0042, Lucca, Not set
Local Institution - 0041, Milano, Not set
Local Institution - 0043, Napoli, Not set
Local Institution - 0101, Fukushima-shi, Fukushima
Local Institution - 0118, Maebashi-shi, Gunma
Local Institution - 0128, Ota-shi, Gunma
Local Institution - 0138, Hiroshima-shi, Hiroshima
Local Institution - 0137, Hiroshima-shi, Hiroshima
Local Institution - 0127, Sapporo-shi, Hokkaido
Local Institution - 0131, Akashi-shi, Hyogo
Local Institution - 0119, Himeji-shi, Hyogo
Local Institution - 0104, Kobe-shi, Hyogo
Local Institution - 0115, Kanazawa-shi, Ishikawa
Local Institution - 0100, Shiwa-gun, Iwate
Local Institution - 0129, Yokohama-shi, Kanagawa
Local Institution - 0114, Yokohama-Shi, Kanagawa
Local Institution - 0134, Yokohama-shi, Kanagawa
Local Institution - 0116, Niigata-shi, Niigata
Local Institution - 0136, Okayama-shi, Okayama
Local Institution - 0135, Habikino-shi, Osaka
Local Institution - 0103, Osaka-Sayama, Osaka
Local Institution - 0102, Kitaadachi-gun, Saitama
Local Institution - 0132, Ube-shi, Yamaguchi
Local Institution - 0130, Osaka, Not set
Local Institution - 0077, La Paz, BAJA Californa SUR
Local Institution - 0061, Guadalajara, Jalisco
Local Institution - 0075, Veracruz, Veracruz, Not set
Local Institution - 0087, Bydgoszcz, Not set
Local Institution - 0022, Bytom, Not set
Local Institution - 0085, Gdańsk, Not set
Local Institution - 0034, Bucharest, Not set
Local Institution - 0031, Cluj Napoca, Not set
Local Institution - 0032, Craiova, Not set
Local Institution - 0024, Moscow, Not set
Local Institution - 0025, St.petersburg, Not set
Local Institution - 0054, A Coruña, Not set
Local Institution - 0053, Barcelona, Not set
Local Institution - 0052, Madrid, Not set
Local Institution - 0055, Malaga, Not set
Local Institution - 0056, Valencia, Not set
Local Institution - 0050, Guildford, Not set
Local Institution - 0049, London, Not set
Local Institution - 0048, Tauton, Not set
Conditions: Non-Small Cell Lung Cancer
Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer
Active Not Recruiting
Chemoradiation has been the standard treatment for advanced cervical cancer for a decade, but one third of women still die from a failure to control systemic disease. In a recent multicentre phase II trial of 46 women the investigators found that, 68% of women had tumours that responded to weekly induction chemotherapy prior to chemoradiation. The induction chemotherapy had acceptable toxicity and did not compromise the standard chemoradiation treatment. In addition, the overall survival and pro... Read More
Chemoradiation has been the standard treatment for advanced cervical cancer for a decade, but one third of women still die from a failure to control systemic disease. In a recent multicentre phase II trial of 46 women the investigators found that, 68% of women had tumours that responded to weekly induction chemotherapy prior to chemoradiation. The induction chemotherapy had acceptable toxicity and did not compromise the standard chemoradiation treatment. In addition, the overall survival and progression free survival at 3 years was 66% (95% CI 4779). These results, together with acceptable toxicity, provide justification for evaluating induction chemotherapy prior to chemoradiation in a randomised phase III trial. The investigators aim to investigate in a randomised trial whether additional induction chemotherapy given on a weekly schedule immediately before standard chemoradiation leads to an improvement in overall survival. The investigators plan to recruit 770 women with locally advanced cervical cancer who are eligible for standard chemoradiation, they will be randomised to weekly carboplatin and paclitaxel chemotherapy for 6 weeks followed by chemoradiation or to chemoradiation alone. The trial will recruit for 4 years with 5 years of follow up period. Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: Instituto do Câncer do Estado de São Paulo, São Paulo, Not set +34 locations
Instituto do Câncer do Estado de São Paulo, São Paulo, Not set
Chittaranjan National Cancer Institute (CNCI), Kolkata, Not set
Saroj Gupta Cancer Centre and Research Institute, Kolkata, Not set
Istituto Europeo di Oncologia, Milan, Lombardy
Instituto Nacional de Cancerologia (INCAN), Mexico City, Not set
North Devon District Hospital, Barnstaple, Devon
University College London Hospital, London, Greater London
Weston Park Hospital, Sheffield, South Yorkshire
Belfast City Hospital, Belfast, Not set
Pilgrim Hospital, Boston, Not set
Royal Sussex County Hospital, Brighton, Not set
Velindre Cancer Centre, Cardiff, Not set
Cheltenham General Hospital, Cheltenham, Not set
Royal Derby Hospital, Derby, Not set
Royal Devon and Exeter NHS Foundation Trust, Exeter, Not set
Beatson WOSCC, Glasgow, Not set
Gloucester Royal Hospital, Gloucester, Not set
Grantham and District Hospital, Grantham, Not set
Castle Hill Hospital, Hull, Not set
Leicester Royal Infirmary, Leicester, Not set
Lincoln County Hospital, Lincoln, Not set
Guy's and St Thomas' NHS Foundation Trust, London, Not set
Imperial College Healthcare NHS Trust, London, Not set
St Bart's Hospital, London, Not set
The Christie NHS Foundation Trust, Manchester, Not set
James Cook University Hospital, Middlesbrough, Not set
Northampton General Hospital, Northampton, Not set
Norfolk and Norwich University Hospital, Norwich, Not set
Nottingham University Hospitals NHS Trust, Nottingham, Not set
Derriford Hospital, Plymouth, Not set
Southampton General Hospital, Southampton, Not set
Royal Stoke University Hospital, Stoke-On-Trent, Not set
Royal Cornwall Hospital, Truro, Not set
The Clatterbridge Cancer Centre, Wirral, Not set
New Cross Hospital, Wolverhampton, Not set
Conditions: Cervical Cancer
Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features
Recruiting
The RAINBO umbrella program consists of four clinical trials investigating new adjuvant therapies in endometrial cancer patients. Eligible patients will be assigned to one of the four RAINBO trials based on the molecular profile of their cancer:
* p53 abnormal endometrial cancer patients to the p53abn-RED trial
* mismatch repair deficient endometrial cancer patients to the MMRd-GREEN trial
* no specific molecular profile endometrial cancer patients to NSMP-ORANGE trial
* POLE mutant endometrial... Read More
The RAINBO umbrella program consists of four clinical trials investigating new adjuvant therapies in endometrial cancer patients. Eligible patients will be assigned to one of the four RAINBO trials based on the molecular profile of their cancer:
* p53 abnormal endometrial cancer patients to the p53abn-RED trial
* mismatch repair deficient endometrial cancer patients to the MMRd-GREEN trial
* no specific molecular profile endometrial cancer patients to NSMP-ORANGE trial
* POLE mutant endometrial cancer patients to the POLEmut-BLUE trial Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: The POLEmut-BLUE trial: Princess Margaret Cancer Centre, University of Toronto, Toronto, Not set +13 locations
The POLEmut-BLUE trial: Princess Margaret Cancer Centre, University of Toronto, Toronto, Not set
The POLEmut-BLUE trial: University of British Columbia, Vancouver, Not set
The p53abn-RED trial: Institute Gustave Roussy, Villejuif, Not set
Amsterdam University Medical Center, Amsterdam, Not set
Amphia Ziekenhuis, Breda, Not set
Instituut Verbeeten, Breda, Not set
Haags Medisch Centrum, Den Haag, Not set
Catharina Ziekenhuis, Eindhoven, Not set
Medisch Spectrum Twente, Enschede, Not set
Universitair Medisch Centrum Groningen, Groningen, Not set
The MMRd-GREEN trial: Leiden University Medical Center, Leiden, Not set
Erasmus Medical Center, Rotterdam, Not set
The NSMP-ORANGE trial: Barts Health NHS Trust, London, Not set
The NSMP-ORANGE trial: Manchester Academic Health Science Centre, St Mary's Hospita, Manchester, Not set
Conditions: Endometrial Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Active Not Recruiting
Researchers are looking for new ways to treat muscle-invasive bladder cancer (MIBC). MIBC is a type of cancer that has not spread from the muscles in the bladder to other parts of the body.
MIBC is treated by having surgery to remove the bladder (cystectomy). Not all people choose to have surgery and want to keep their bladder using other treatments.
Chemoradiotherapy (CRT)- is a type of non-surgical treatment for MIBC which combines Chemotherapy (a treatment with medicine to destroy cancer ce... Read More
Researchers are looking for new ways to treat muscle-invasive bladder cancer (MIBC). MIBC is a type of cancer that has not spread from the muscles in the bladder to other parts of the body.
MIBC is treated by having surgery to remove the bladder (cystectomy). Not all people choose to have surgery and want to keep their bladder using other treatments.
Chemoradiotherapy (CRT)- is a type of non-surgical treatment for MIBC which combines Chemotherapy (a treatment with medicine to destroy cancer cells or stop them growing) and Radiation therapy (a treatment that uses beams of intense energy \[like X-rays\] to shrink or get rid of tumors).
Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer.
A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand if the study medicine works.
The goal of this study is to learn: 1. If a study medicine pembrolizumab given with Chemoradiotherapy (CRT) can help people live longer without their cancer growing, spreading, or coming back compared to placebo given with CRT. 2.About the safety and how well people tolerate CRT alone or in combination with pembrolizumab. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Washington Cancer Institute at MedStar Washington Hospital Center ( Site 0041), Washington, District of Columbia +125 locations
Washington Cancer Institute at MedStar Washington Hospital Center ( Site 0041), Washington, District of Columbia
Bay Pines VA Medical Center ( Site 0055), Bay Pines, Florida
AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0004), Orlando, Florida
Norton Cancer Institute ( Site 0044), Louisville, Kentucky
Pikeville Medical Center ( Site 0009), Pikeville, Kentucky
Baltimore VA Medical Center ( Site 0054), Baltimore, Maryland
Washington University ( Site 0003), Saint Louis, Missouri
Summit Medical Group Cancer Center ( Site 6008), Florham Park, New Jersey
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0005), Hackensack, New Jersey
New York Oncology Hematology P.C ( Site 0024), Albany, New York
Roswell Park Cancer Institute ( Site 6009), Buffalo, New York
Winthrop University Hospital ( Site 0069), Mineola, New York
New York University Perlmutter Cancer Center ( Site 0001), New York, New York
Fairview Hospital-Moll Cancer Center ( Site 6013), Cleveland, Ohio
Cleveland Clinic Main ( Site 0062), Cleveland, Ohio
Cleveland Clinic - Hillcrest Hospital-Hillcrest Hospital Cancer Center ( Site 6012), Mayfield Heights, Ohio
MidLantic urology ( Site 0070), Bala-Cynwyd, Pennsylvania
Saint Francis Cancer Center ( Site 0026), Greenville, South Carolina
Carolina Urologic Research Center ( Site 0002), Myrtle Beach, South Carolina
Urology San Antonio Research ( Site 6010), San Antonio, Texas
Inova Schar Cancer Institute ( Site 6006), Fairfax, Virginia
West Virginia University - Charleston Area Medical Center ( Site 6003), Charleston, West Virginia
Froedtert and Medical College of Wisconsin ( Site 0022), Milwaukee, Wisconsin
Liverpool Hospital ( Site 0220), Liverpool, New South Wales
GenesisCare North Shore ( Site 0217), St Leonards, New South Wales
Monash Medical Centre ( Site 0216), Clayton, Victoria
Austin Health ( Site 0218), Heidelberg, Victoria
Sir Charles Gairdner Hospital ( Site 0223), Nedlands, Western Australia
Oncocentro Valdivia ( Site 7055), Valdivia, Los Rios
FALP ( Site 7056), Santiago, Region M. De Santiago
Bradfordhill-Clinical Area ( Site 7051), Santiago, Region M. De Santiago
ONCOCENTRO APYS-ACEREY ( Site 7054), Viña del Mar, Valparaiso
Bradford Hill Norte ( Site 7052), Antofagasta, Not set
Fakultni nemocnice Olomouc ( Site 0559), Olomouc, Not set
2. LF UK a FN Motol ( Site 0555), Praha 5, Not set
Nemocnice Na Bulovce ( Site 0556), Praha 8, Not set
Herlev og Gentofte Hospital. ( Site 0401), Herlev, Hovedstaden
Odense Universitetshospital ( Site 0403), Odense, Syddanmark
North Estonia Medical Centre Foundation ( Site 0081), Tallin, Harjumaa
Tartu University Hospital ( Site 0079), Tartu, Tartumaa
Institut Sainte Catherine ( Site 0121), Avignon, Provence-Alpes-Cote-d Azur
CHU Amiens Picardie Site Sud Amiens ( Site 0123), Amiens, Somme
Institut Curie ( Site 0112), Paris, Not set
A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 0115), Paris, Not set
Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0146), Guatemala, Not set
Oncomedica ( Site 0145), Guatemala, Not set
Grupo Medico Angeles ( Site 0143), Guatemala, Not set
Medi-K Cayala ( Site 0142), Guatemala, Not set
Centro Medico Integral De Cancerología (CEMIC) ( Site 0144), Quetzaltenango, Not set
BAZ Megyei Korhaz. Klinikai Onkologia es Sugarterapias Centrum ( Site 0092), Miskolc, Borsod-Abauj-Zemplen
Petz Aladar Megyei Oktato Korhaz ( Site 0099), Gyor, Gyor-Moson-Sopron
Egeszsegugyi Tudomanyos Tanacs Klinikai Farmakologiai Etikai Bizottsaga ( Site 0095), Budapest, Not set
Debreceni Egyetem Klinikai Kozpont ( Site 0097), Debrecen, Not set
Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 0091), Kaposvar, Not set
Soroka Medical Center-Oncology ( Site 7031), Be'er Sheva, Not set
Rambam Health Care Campus-Oncology Division ( Site 0088), Haifa, Not set
Hadassah Medical Center. Ein Kerem ( Site 0086), Jerusalem, Not set
Rabin Medical Center ( Site 7032), Petah Tikva, Not set
Chaim Sheba Medical Center ( Site 0087), Ramat Gan, Not set
Sourasky Medical Center ( Site 0089), Tel Aviv, Not set
Fondazione Policlinico Universitario Campus Bio-Medico-Radiation Oncology ( Site 7041), Roma, Lazio
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0186), Milano, Lombardia
IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 0193), Bari, Puglia
AOU Careggi ( Site 0191), Firenze, Not set
Ospedale Civile di Macerata ( Site 0190), Macerata, Not set
Ospedale San Raffaele ( Site 0194), Milano, Not set
Azienda Ospedaliero - Universitaria Policlinico di Modena ( Site 0188), Modena, Not set
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0192), Napoli, Not set
Hirosaki University Hospital ( Site 0602), Hirosaki, Aomori
University of Tsukuba Hospital ( Site 0605), Tsukuba, Ibaraki
Osaka Medical and Pharmaceutical University Hospital ( Site 0604), Takatsuki, Osaka
Nagasaki University Hospital ( Site 0600), Nagasaki, Not set
Institute of Science Tokyo Hospital ( Site 0601), Tokyo, Not set
Tokyo Metropolitan Komagome Hospital ( Site 0606), Tokyo, Not set
National Cancer Center ( Site 0202), Gyeonggi-do, Kyonggi-do
Seoul National University Bundang Hospital ( Site 0204), Seongnam-si, Kyonggi-do
Asan Medical Center ( Site 0200), Songpagu, Seoul
Chungnam National University Hospital ( Site 0203), Daejeon, Taejon-Kwangyokshi
Korea University Anam Hospital ( Site 0205), Seoul, Not set
Severance Hospital Yonsei University Health System ( Site 0201), Seoul, Not set
Pauls Stradins Clinical University Hospital ( Site 0073), Riga, Not set
Hospital Universiti Sains Malaysia ( Site 0237), Kubang Kerian, Kelantan
Hospital Pulau Pinang ( Site 0239), Penang, Pulau Pinang
Hospital Kuala Lumpur ( Site 0238), Kuala Lumpur, Not set
University Malaya Medical Centre ( Site 0236), Kuala Lumpur, Not set
Netherlands Cancer Institute (NKI) ( Site 0183), Amsterdam, Noord-Holland
Erasmus MC ( Site 0182), Rotterdam, Zuid-Holland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 0153), Krakow, Malopolskie
Mazowiecki Szpital Wojewódzki w Siedlcach ( Site 0154), Siedlce, Mazowieckie
Szpital Wojewodzki im. Mikolaja Kopernika ( Site 0152), Koszalin, Zachodniopomorskie
Unidade Local de Saude Loures-Odivelas - Hospital Beatriz Angelo ( Site 0303), Loures, Lisboa
Centro Hospitalar e Universitario de Coimbra ( Site 0306), Coimbra, Not set
Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 0302), Lisboa, Not set
Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 0305), Lisboa, Not set
Advance Urology and Laparoscopic Center ( Site 0281), Ponce, Not set
PAN American Center Oncologic ( Site 0280), San Juan, Rio Piedras, Not set
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0249), Cluj Napoca, Cluj
S.C. Radiotherapy Center Cluj S.R.L ( Site 0252), Cluj-Napoca, Cluj
S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0248), Craiova, Dolj
Policlinica Oncomed SRL ( Site 0254), Timisoara, Timis
MEMORIAL HEALTHCARE INTERNATIONAL S.R.L. ( Site 0253), Bucuresti, Not set
Institutul Oncologic-Oncologie Medicala ( Site 0256), Cluj, Not set
Institutul Regional de Oncologie Iasi ( Site 0255), Iasi, Not set
Instituto Catalan de Oncologia - ICO ( Site 0103), L Hospitalet De Llobregat, Barcelona
Hospital La Fe de Valencia ( Site 0105), Valencia, Valenciana, Comunitat
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 0106), Sevilla, Not set
University of Health Sciences,Gulhane School of Medicine-Oncology ( Site 0509), Ankara, Not set
Ankara Universitesi Tip Fakultesi. ( Site 0502), Ankara, Not set
Istanbul Uni. Cerrahpasa Tip Fakultesi ( Site 0501), Istanbul, Not set
T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Baki-Istanbul Bakirkoy Sadi Konuk Training (, Istanbul, Not set
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0504), Istanbul, Not set
Ege University Medical Faculty ( Site 0508), Izmir, Not set
Karadeniz Teknik Universitesi Tip Fakultesi ( Site 0503), Trabzon, Not set
Clinical oncology dispensary of Dnipro ( Site 0133), Dnipro, Dnipropetrovska Oblast
Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 0139), Kharkiv, Kharkivska Oblast
MNPE Regional Center of Oncology ( Site 0134), Kharkiv, Kharkivska Oblast
Ukranian Center of TomoTherapy ( Site 0140), Kropyvnytskiy, Kirovohradska Oblast
SNPE National Cancer Institute ( Site 0136), Kyiv, Kyivska Oblast
Kyiv City Clinical Oncology Center ( Site 0135), Kyiv, Not set
Betsi Cadwaladr University Health Board ( Site 0447), Rhyl, Denbighshire
South Devon Healthcare Foundation Trust. Torbay Hospital ( Site 0444), Torquay, Devon
Royal Preston Hospital ( Site 0449), Preston, Lancashire
University College London Hospitals NHS Foundation Trust ( Site 0445), London, London, City Of
The Royal Marsden NHS Foundation Trust. ( Site 0442), London, London, City Of
Nottingham University Hospital NHS Trust ( Site 0250), Nottingham, Nottinghamshire
Darlington Memorial Hospital NHS Trust ( Site 0446), Darlington, Not set
Conditions: Urinary Bladder Neoplasms
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Active Not Recruiting
The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy.
The primary study hypotheses are that pembrolizumab is superior to the combination of carboplatin and paclitaxel with respect to Progression Free Survival (PFS) per Response Ev... Read More
The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy.
The primary study hypotheses are that pembrolizumab is superior to the combination of carboplatin and paclitaxel with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and Overall Survival (OS). Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: HonorHealth-USOR HonorHealth ( Site 8000), Phoenix, Arizona +194 locations
HonorHealth-USOR HonorHealth ( Site 8000), Phoenix, Arizona
Moores Cancer Center ( Site 0037), La Jolla, California
Kaiser Permanente Riverside Medical Center ( Site 0045), Riverside, California
Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0013), New Haven, Connecticut
Mount Sinai Cancer Center ( Site 0018), Miami Beach, Florida
Sarasota Memorial Hospital ( Site 0005), Sarasota, Florida
Northside Hospital ( Site 0017), Atlanta, Georgia
Southeastern Regional Medical Center ( Site 0046), Newnan, Georgia
Midwestern Regional Medical Center,Inc. DBA CTCA, Chicago ( Site 0003), Zion, Illinois
St. Vincent Hospital and Health Care Center, Inc ( Site 0006), Indianapolis, Indiana
Baptist Health Lexington ( Site 0042), Lexington, Kentucky
Maryland Oncology Hematology, P.A.-USOR Maryland Oncology Hematology, P.A. ( Site 8002), Rockville, Maryland
University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 0008), Worcester, Massachusetts
Karmanos Cancer Institute ( Site 0029), Detroit, Michigan
St. Dominic's Hospital ( Site 0024), Jackson, Mississippi
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0026), Hackensack, New Jersey
The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0023), New York, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0016), New York, New York
Icahn School of Medicine at Mount Sinai ( Site 0052), New York, New York
Memorial Sloan Kettering Cancer Center ( Site 0009), New York, New York
FirstHealth Clinical Trials ( Site 0050), Pinehurst, North Carolina
Sanford Medical Center ( Site 0054), Bismarck, North Dakota
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0055), Fargo, North Dakota
University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0039), Cincinnati, Ohio
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio
Providence Portland Medical Center ( Site 0031), Portland, Oregon
Sidney Kimmel Cancer Center - Jefferson Health ( Site 0053), Philadelphia, Pennsylvania
University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0034), Pittsburgh, Pennsylvania
AHN West Penn Hospital ( Site 0011), Pittsburgh, Pennsylvania
Asplundh Cancer Pavilion ( Site 0014), Willow Grove, Pennsylvania
Sanford Cancer Center-Gynecologic Oncology ( Site 0002), Sioux Falls, South Dakota
Texas Oncology - Austin-USOR Texas Oncology - Austin ( Site 8003), Austin, Texas
Texas Oncology - Dallas-USOR Texas Oncology - Dallas (Sammons) ( Site 8005), Dallas, Texas
Texas Oncology - Tyler-USOR Texas Oncology - Northeast Texas ( Site 8004), Tyler, Texas
VCU Health Adult Outpatient Pavillion ( Site 0022), Richmond, Virginia
Northern Cancer Institute ( Site 0206), St Leonards, New South Wales
Westmead Hospital-Department of Gynaecological Oncology ( Site 0201), Westmead, New South Wales
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si, Brisbane, Queensland
Monash Health ( Site 0202), Clayton, Victoria
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0207), Melbourne, Victoria
Epworth Freemasons ( Site 0203), Melbourne, Victoria
St. John of God Subiaco Hospital-Oncology Clinical Trials Unit ( Site 0204), Subiaco, Western Australia
Institut Jules Bordet-Medicine Oncology ( Site 0321), Bruxelles, Bruxelles-Capitale, Region De
Grand Hôpital de Charleroi-Oncology & Hematology ( Site 0323), Charleroi, Hainaut
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman ( Site 0320), Liège, Liege
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 3005), Natal, Rio Grande Do Norte
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 3001), São Paulo, Sao Paulo
A. C. Camargo Cancer Center-CAPEC ( Site 3003), Sao Paulo, Not set
Cross Cancer Institute ( Site 0513), Edmonton, Alberta
BC Cancer Kelowna ( Site 0517), Kelowna, British Columbia
BC Cancer Vancouver-Clinical Trials Unit ( Site 0518), Vancouver, British Columbia
Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0509), Toronto, Ontario
Princess Margaret Cancer Centre ( Site 0510), Toronto, Ontario
Jewish General Hospital ( Site 0504), Montreal, Quebec
Centre Hospitalier de l'Université de Montréal ( Site 0519), Montréal, Quebec
McGill University Health Centre ( Site 0505), Montréal, Quebec
Saskatoon Cancer Center-Clinical Research Department ( Site 0520), Saskatoon, Saskatchewan
FALP-UIDO ( Site 0602), Santiago, Region M. De Santiago
Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 0604), Santiago, Region M. De Santiago
Bradfordhill-Clinical Area ( Site 0603), Santiago, Region M. De Santiago
Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 0730), Hefei, Anhui
Beijing Obstetric and Gynecology Hospital ( Site 0740), Beijing, Beijing
Peking University First Hospital ( Site 0723), Beijing, Beijing
Beijing Cancer hospital ( Site 0715), Beijing, Beijing
Southwest Hospital of Third Military Medical University ( Site 0719), Chongqing, Chongqing
2nd Affiliated Hospital Chongqing Medical Universi ( Site 0745), Chongqing, Chongqing
Fuling Central Hospital ( Site 0733), Fulingqu, Chongqing
Fujian Provincial Cancer Hospital ( Site 0720), Fuzhou, Fujian
SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 0710), Guangzhou, Guangdong
Cancer Hospital of Shantou University Medical College ( Site 0732), Shantou, Guangdong
Affiliated Hospital of Guangdong Medical College ( Site 0731), Zhanjiang, Guangdong
Guangxi Medical University Affiliated Tumor Hospital-Gynecological oncology ( Site 0704), Nanning, Guangxi
Hainan General Hospital ( Site 0703), Haikou, Hainan
Harbin Medical University Cancer Hospital ( Site 0711), Harbin, Heilongjiang
Henan Cancer Hospital ( Site 0713), Zhengzhou, Henan
Wuhan Union Hospital-Medical Oncology ( Site 0716), Wuhan, Hubei
Xiangya Hospital Central South University-Gynecology ( Site 0708), Changsha, Hunan
Hunan Cancer Hospital ( Site 0709), Changsha, Hunan
Jiangsu Province Hospital-Oncology Department ( Site 0707), Nanjing, Jiangsu
The First Affiliated Hospital of Nanchang University ( Site 0729), Nanchang, Jiangxi
The First Hospital of Jilin University ( Site 0705), Changchun, Jilin
Shaanxi Provincial Cancer Hospital ( Site 0714), XI An, Shaanxi
Binzhou Medical University Hospital-Oncology department ( Site 0735), Binzhou, Shandong
Obstetrics & Gynecology Hospital of Fudan University ( Site 0702), Shanghai, Shanghai
Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 0717), Shanghai, Shanghai
West China Second University Hospital Sichuan University ( Site 0701), Chengdu, Sichuan
Tianjin Medical University Cancer Institute and Hospital ( Site 0706), Tianjin, Tianjin
Yunnan Province Cancer Hospital-Gynecology Department ( Site 0721), Kunming, Yunnan
The Affiliated Women's Hospital of Zhejiang University-Obstetrics and Gynecology ( Site 0726), Hangzhou, Zhejiang
Zhejiang Cancer Hospital-Oncology ( Site 0700), Hangzhou, Zhejiang
The First Affiliated Hospital of Wenzhou Medical University-Gynecology ( Site 0725), Wenzhou, Zhejiang
Fakultní nemocnice Brno Bohunice-Gynekologicko-porodnicka klinika ( Site 0404), Brno, Brno-mesto
Fakultni nemocnice Ostrava-Gynekologicko-porodnicka klinika ( Site 0403), Ostrava, Moravskoslezsky Kraj
Nemocnice AGEL Novy Jicin a.s.-Oddeleni radioterapie a onkologie ( Site 0406), Nový Jiín, Novy Jicin
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0402), Olomouc, Olomoucky Kraj
Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 0405), Praha, Praha 2
Fakultni nemocnice Bulovka-Gynekologicko-porodnicka klinika ( Site 0401), Praha, Praha 8
Nemocnice Tomase Bati ve Zline-Onkologické oddělení ( Site 0407), Zlín, Zlinsky Kraj
Fakultni nemocnice Kralovske Vinohrady-Gynekologicko-porodnická klinika ( Site 0408), Praha 10, Not set
Rigshospitalet ( Site 0903), Copenhagen, Hovedstaden
Herlev and Gentofte Hospital ( Site 0902), Copenhagen, Hovedstaden
Aalborg Universitetshospital, Syd ( Site 0905), Aalborg, Nordjylland
Roskilde Sygehus-Oncology department ( Site 0904), Roskilde, Sjaelland
Tampereen yliopistollinen sairaala-Gynecology and Obstetrics ( Site 1001), Tampere, Pirkanmaa
Kuopion Yliopistollinen Sairaala ( Site 1002), Kuopio, Pohjois-Savo
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 1003), Helsinki, Uusimaa
Universitaetsklinikum Ulm ( Site 1106), Ulm, Baden-Wurttemberg
Universitätsklinikum Bonn-Gynaecological oncology ( Site 1105), Bonn, Nordrhein-Westfalen
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur, Dresden, Sachsen
Charité Campus Virchow-Klinikum ( Site 1103), Berlin, Not set
Országos Onkológiai Intézet-Ngyógyászat ( Site 1201), Budapest, Not set
Bon Secours Cork Hospital ( Site 1305), Cork, Not set
St. James's Hospital-Cancer clinical trials office ( Site 1301), Dublin, Not set
Soroka Medical Center ( Site 1403), Be'er Sheva, Not set
Rambam Health Care Campus-Gyneco-oncology unit ( Site 1402), Haifa, Not set
Edith Wolfson Medical Center-Obstetrics & Gynecology ( Site 1405), Holon, Not set
Shaare Zedek Medical Center ( Site 1404), Jerusalem, Not set
Sheba Medical Center ( Site 1401), Ramat Gan, Not set
Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Sperimentale Uro-Genitale ( Site 1, Napoli, Campania
IRCCS - AOU di Bologna-SSD Oncologia medica Addarii ( Site 1503), Bologna, Emilia-Romagna
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Oncologia Medica ( Site 1513), Meldola, Emilia-Romagna
Fondazione Policlinico Universitario Agostino Gemelli-Ginecologia Oncologica ( Site 1502), Roma, Lazio
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 150, Milan, Lombardia
Ospedale Mauriziano-SCDU ONCOLOGIA MEDICA ( Site 1514), Torino, Piemonte
Istituto Nazionale Tumori Regina Elena-Oncologia Medica 1 ( Site 1504), Rome, Roma
Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1509), Firenze, Toscana
AULSS8 Berica-Ospedale S.Bortolo-ONCOLOGIA CLINICA ( Site 1510), Vicenza, Veneto
Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 1506), Milano, Not set
National Cancer Center Hospital East ( Site 1604), Kashiwa, Chiba
National Hospital Organization Shikoku Cancer Center ( Site 1611), Matsuyama, Ehime
Ehime University Hospital ( Site 1614), Toon, Ehime
Kurume University Hospital ( Site 1612), Kurume, Fukuoka
Gunma Prefectural Cancer Center-Gynecology ( Site 1603), Ota, Gunma
Hokkaido University Hospital ( Site 1601), Sapporo, Hokkaido
Tsukuba University Hospital ( Site 1618), Tsukuba, Ibaraki
Iwate Medical University Hospital ( Site 1602), Shiwa-gun Yahaba-cho, Iwate
Niigata University Medical & Dental Hospital ( Site 1613), Chuo-ku, Niigata, Niigata
Saitama Medical University International Medical Center ( Site 1605), Hidaka-shi, Saitama
Shizuoka Cancer Center ( Site 1609), Nagaizumi-cho,Sunto-gun, Shizuoka
National Cancer Center Hospital ( Site 1607), Chuo-ku, Tokyo
Japanese Foundation for Cancer Research ( Site 1616), Koto, Tokyo
The Jikei University Hospital ( Site 1615), Minato-ku, Tokyo
Keio university hospital ( Site 1606), Shinjyuku-ku, Tokyo
National Hospital Organization Kyushu Cancer Center ( Site 1608), Fukuoka, Not set
Osaka International Cancer Institute ( Site 1617), Osaka, Not set
Seoul National University Hospital ( Site 2302), Seoul, Not set
Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 2301), Seoul, Not set
Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 2303), Seoul, Not set
Gangnam Severance Hospital ( Site 2304), Seoul, Not set
Radboudumc-Medical Oncology ( Site 1703), Nijmegen, Gelderland
Maastricht UMC+ ( Site 1709), Maastricht, Limburg
Catharina Ziekenhuis-Oncology ( Site 1704), Eindhoven, Noord-Brabant
Amsterdam UMC, locatie AMC ( Site 1706), Amsterdam, Noord-Holland
Leids Universitair Medisch Centrum-Medical Oncology ( Site 1702), Leiden, Zuid-Holland
Erasmus Medisch Centrum-Medical Oncology ( Site 1701), Rotterdam, Zuid-Holland
University Medical Center Groningen ( Site 1707), Groningen, Not set
Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 1705), Utrecht, Not set
Auckland City Hospital-Cancer & Blood Research ( Site 1801), Auckland, Not set
Oslo universitetssykehus, Radiumhospitalet ( Site 1901), Oslo, Not set
Centrum Onkologii Ziemi Lubelskiej ( Site 2006), Lublin, Lubelskie
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2007), Siedlce, Mazowieckie
Szpital Kliniczny im. Księżnej Anny Mazowieckiej ( Site 2009), Warsaw, Mazowieckie
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Sit, Warszawa, Mazowieckie
Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 2003), Bialystok, Podlaskie
Narodowy Instytut Onkologii - Oddzial w Gliwicach-III Klinika Radioterapii i Chemioterapii ( Site 20, Gliwice, Slaskie
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 2010), Kielce, Swietokrzyskie
Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Me-Oddzial Ginekologii Onkologicznej ( Sit, Poznan, Wielkopolskie
Moscow City Oncology Hospital #62 ( Site 2204), Krasnogorsk, Moskovskaya Oblast
Yaroslavl Regional Cancer Hospital-Oncology ( Site 2202), Yaroslavl, Yaroslavskaya Oblast
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2406), Hospitalet, Barcelona
CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2405), A Coruña, La Coruna
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 2402), Madrid, Madrid, Comunidad De
COMPLEJO HOSPITALARIO DE NAVARRA ( Site 2407), Pamplona, Navarra
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 2404), Valencia, Valenciana, Comunitat
Hospital Universitari Vall d'Hebron ( Site 2403), Barcelona, Not set
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 2401), Sevilla, Not set
Skånes Universitetssjukhus Lund-Department of Hematology ( Site 2504), Lund, Skane Lan
Karolinska Universitetssjukhuset Solna ( Site 2502), Solna, Stockholms Lan
Norrlands universitetssjukhus-Cancercentrum ( Site 2503), Umeå, Vasterbottens Lan
Taichung Veterans General Hospital ( Site 2602), Taichung, Not set
NATIONAL CHENG-KUNG UNI. HOSP. ( Site 2604), Tainan, Not set
National Taiwan University Hospital ( Site 2603), Taipei, Not set
Mackay Memorial Hospital ( Site 2601), Taipei, Not set
Taipei Veterans General Hospital ( Site 2605), Taipei, Not set
Istanbul Universitesi Cerrahpasa ( Site 2702), Fatih, Istanbul
Hacettepe Universite Hastaneleri-oncology hospital ( Site 2704), Ankara, Not set
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 2706), Ankara, Not set
Akdeniz Universitesi Hastanesi ( Site 2701), Antalya, Not set
Istanbul University Capa Campus-department of obstetrics and gynaecology ( Site 2705), Istanbul, Not set
T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma, Istanbul, Not set
St Bartholomew's Hospital ( Site 2804), London, England
The Christie ( Site 2807), Manchester, England
The Beatson West of Scotland Cancer Centre ( Site 2805), Glasgow, Glasgow City
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2806), London, London, City Of
Hammersmith Hospital-Medical Oncology ( Site 2808), London, London, City Of
Conditions: Endometrial Neoplasms
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Completed
The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.
The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2024
Locations: Southern Cancer Center, Inc., Mobile, Alabama +289 locations
Southern Cancer Center, Inc., Mobile, Alabama
Local Institution - 0017, San Francisco, California
Local Institution - 0021, New Haven, Connecticut
Local Institution - 0001, Atlanta, Georgia
Local Institution - 0013, Marietta, Georgia
Local Institution - 0004, Lexington, Kentucky
Local Institution - 0115, Saint Louis, Missouri
Local Institution - 0005, Buffalo, New York
Local Institution - 0019, New York, New York
Local Institution - 0014, Cleveland, Ohio
Local Institution - 0009, Columbus, Ohio
Local Institution - 0007, Allentown, Pennsylvania
Local Institution - 0075, Langhorne, Pennsylvania
Local Institution - 0299, Philadelphia, Pennsylvania
Local Institution - 0012, Philadelphia, Pennsylvania
Local Institution - 0015, Sayre, Pennsylvania
Local Institution - 0008, Charleston, South Carolina
Local Institution - 0080, Greenville, South Carolina
Local Institution - 0010, Greenville, South Carolina
Local Institution - 0020, Nashville, Tennessee
Local Institution - 0306, Dallas, Texas
Local Institution - 0003, Dallas, Texas
Local Institution - 0102, Houston, Texas
Local Institution - 0011, Salt Lake City, Utah
Local Institution - 0074, Kennewick, Washington
Local Institution - 0170, Berazategui, Buenos Aires
Local Institution - 0171, Capital Federal, Buenos Aires
Local Institution - 0172, Ciudad Autonoma De Buenos Aire, Buenos Aires
Local Institution - 0176, Ciudad de Buenos Aires, Buenos Aires
Local Institution - 0296, Mar Del Plata, Buenos Aires
Local Institution - 0177, Viedma, RIO Negro
Local Institution - 0130, San Miguel de Tucuman, Tucuman
Local Institution - 0268, Cordoba, Not set
Local Institution - 0272, Córdoba, Not set
Local Institution - 0297, Córdoba, Not set
Local Institution - 0182, Garran, Australian Capital Territory
Local Institution - 0301, Blacktown, New South Wales
Local Institution - 0300, Gosford, New South Wales
Local Institution - 0045, Brisbane, Queensland
Local Institution - 0046, Elizabeth Vale, South Australia
Local Institution - 0043, Clayton, Victoria
Local Institution - 0042, Fitzroy, Victoria
Local Institution - 0180, Perth, Western Australia
Local Institution - 0040, Murdoch, Not set
Local Institution - 0183, North Tamworth, Not set
Local Institution - 0241, Graz, Not set
Local Institution - 0240, Vienna, Not set
Local Institution - 0239, Wels, Not set
Local Institution - 0121, Roeselare, West-Vlaanderen
Local Institution - 0030, Edegem, Not set
Local Institution - 0031, Gent, Not set
Local Institution - 0034, Gilly, Not set
Local Institution - 0117, Hasselt, Not set
Local Institution - 0033, Sint Niklaas, Not set
Local Institution - 0125, Salvador, Bahia
Local Institution - 0124, Ijui, RIO Grande DO SUL
Local Institution - 0123, Porto Alegre, Rio Grande Do Sul
Local Institution - 0127, Barretos, Sao Paulo
Local Institution - 0129, Rio De Janeiro, Not set
Local Institution - 0144, Sao Paulo, Not set
Local Institution - 0126, Sao Paulo, Not set
Local Institution - 0128, Sao Paulo, Not set
Local Institution - 0103, Edmonton, Alberta
Local Institution - 0290, St. John's, Newfoundland and Labrador
Local Institution - 0104, London, Ontario
Local Institution - 0122, Montreal, Quebec
Local Institution - 0106, Quebec City, Quebec
Local Institution - 0107, Rimouski, Quebec
Local Institution - 0291, Sherbrooke, Quebec
Local Institution - 0292, Trois-Rivieres, Quebec
Local Institution - 0302, Quebec, Not set
Local Institution - 0173, Santiago, Metropolitana
Local Institution - 0131, Santiago, Región Metropolitana De Santiago
Local Institution - 0174, Vina Del Mar, Valparaiso
Local Institution - 0380, Hefei, Anhui
Local Institution - 0313, Beijing, Beijing
Local Institution - 0315, Beijing, Beijing
Local Institution - 0316, Beijing, Beijing
Local Institution - 0314, Beijing, Beijing
Local Institution - 0365, Chongqing, Chongqing
Local Institution - 0364, Chongqing, Chongqing
Local Institution - 0378, Chongqing, Chongqing
Local Institution - 0322, Guangzhou, Guangdong
Local Institution - 0372, Guangzhou, Guangdong
Local Institution - 0319, Guanzhou, Guangdong
Local Institution - 0323, Haikou, Hainan
Local Institution - 0325, Haerbin, Heilongjiang
Local Institution - 0324, Zhengzhou, Henan
Local Institution - 0379, Zhengzhou, Henan
Local Institution - 0375, Wuhan, Hubei
Local Institution - 0362, Changsha, Hunan
Local Institution - 0347, Nanchang, Jiangxi
Local Institution - 0329, Changchun, Jilin
Local Institution - 0361, Changchun, Jilin
Local Institution - 0359, Shenyang, Liaoning
Local Institution - 0371, Xi'an, Shaanxi
Local Institution - 0333, Xi'an, Shan3xi
Local Institution - 0360, Qingdao, Shandong
Local Institution - 0334, Shanghai, Shanghai
Local Institution - 0376, Chengdu, Sichuan
Local Institution - 0373, Tianjin, Tianjin
Local Institution - 0340, Urumqi, Xinjiang
Local Institution - 0343, Hangzhou, Zhejiang
Local Institution - 0370, Hangzhou, Zhejiang
Local Institution - 0342, Hangzhou, Zhejiang
Local Institution - 0328, Changsha, Not set
Local Institution - 0341, Hangzhou, Not set
Local Institution - 0345, Kunming, Not set
Local Institution - 0336, Shanghai, Not set
Local Institution - 0337, Shanghai, Not set
Local Institution - 0374, Shantou, Not set
Local Institution - 0273, Pereira, Risaralda
Local Institution - 0237, Bogota, Not set
Local Institution - 0238, Bogota, Not set
Local Institution - 0282, Medellin, Not set
Local Institution - 0112, Hradec Kralove, Not set
Local Institution - 0113, Olomouc, Not set
Local Institution - 0111, Praha 4, Not set
Local Institution - 0232, Pribram, Not set
Local Institution - 0270, Oulu, Not set
Local Institution - 0271, Turku, Not set
Local Institution - 0222, Bron, Rhône
Local Institution - 0216, ANGERS Cedex 2, Not set
Local Institution - 0229, Besançon Cedex, Not set
Local Institution - 0283, Caen, Not set
Local Institution - 0218, Creteil, Not set
Local Institution - 0228, Limoges, Not set
Local Institution - 0215, Marseille Cedex 20, Not set
Local Institution - 0230, Paris, Not set
Local Institution - 0227, Pessac, Not set
Local Institution - 0223, Rennes, Not set
Local Institution - 0225, Rouen, Not set
Local Institution - 0221, Saint Priest En Jarez, Not set
Local Institution - 0217, Saint-herblain Cedex, Not set
Local Institution - 0224, Strasbourg, Not set
Local Institution - 0226, Toulon, Not set
Local Institution - 0231, Magdeburg, Sachsen-Anhalt
Local Institution - 0213, Bad Berka, Not set
Local Institution - 0208, Berlin, Not set
Local Institution - 0205, Essen, Not set
Local Institution - 0210, Frankfurt, Not set
Local Institution - 0211, Gera, Not set
Local Institution - 0203, Grosshansdorf, Not set
Local Institution - 0209, Halle, Not set
Local Institution - 0202, Heidelberg, Not set
Local Institution - 0214, Hemer, Not set
Local Institution - 0206, Immenstadt, Not set
Local Institution - 0204, Muenchen, Not set
Local Institution - 0201, Stuttgart, Not set
Local Institution - 0212, Wiesbaden, Not set
Local Institution - 0094, Athens, Attikí
Local Institution - 0095, Heraklion, Not set
Local Institution - 0190, Neo Faliro, Not set
Local Institution - 0101, Thessaloniki, Not set
Local Institution - 0025, Budapest, Not set
Local Institution - 0024, Budapest, Not set
Local Institution - 0026, Matrahaza, Not set
Local Institution - 0054, Dublin 8, Dublin
Local Institution - 0053, Beaumont, Not set
Local Institution - 0055, Galway, Not set
Local Institution - 0100, Limerick, Not set
Local Institution - 0187, Jerusalem, Not set
Local Institution - 0186, Kfar-saba, Not set
Local Institution - 0185, Petach Tikva, Not set
Local Institution - 0184, Tel-hashomer, Not set
Local Institution - 0188, Zerifin, Not set
Local Institution - 0083, Milan, Lombardia
Azienda Ospedaliera Moscati, Avellino, Not set
Local Institution - 0179, Bergamo, Not set
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Not set
Local Institution - 0084, Livorno, Not set
Policlinico G. Martino, Messina, Not set
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Not set
Istituto Nazionale Tumori Fondazione Pascale, Napoli, Not set
Local Institution - 0087, Perugia, Not set
Ospedale Santa Maria delle Croci, Ravenna, Not set
Ifo-Istituto Regina Elena, Roma, Not set
Local Institution - 0089, Roma, Not set
Local Institution - 0085, Terni, Not set
Local Institution - 0153, Nagoya-shi, Aichi
Local Institution - 0152, Nagoya, Aichi
Local Institution - 0148, Kashiwa-shi, Chiba
Local Institution - 0159, Matsuyama, Ehime
Local Institution - 0160, Fukuoka-shi, Fukuoka
Local Institution - 0259, Kurume-shi, Fukuoka
Local Institution - 0255, Ota-shi, Gunma
Local Institution - 0258, Hiroshima-shi, Hiroshima
Local Institution - 0163, Sapporo-shi, Hokkaido
Local Institution - 0253, Sapporo-shi, Hokkaido
Local Institution - 0252, Akashi-shi, Hyogo
Local Institution - 0156, Kobe-shi, Hyogo
Local Institution - 0146, Kanazawa-shi, Ishikawa
Local Institution - 0161, Yokohama-shi, Kanagawa
Local Institution - 0150, Yokohama-Shi, Kanagawa
Local Institution - 0275, Natori-shi, Miyagi
Local Institution - 0254, Sendai-shi, Miyagi
Local Institution - 0145, Sendai-shi, Miyagi
Local Institution - 0164, Niigata-shi, Niigata
Local Institution - 0158, Kurashiki-shi, Okayama
Local Institution - 0155, Hirakata-shi, Osaka
Local Institution - 0154, Osaka-shi, Osaka
Local Institution - 0251, Osakasayama-shi, Osaka
Local Institution - 0257, Takatsuki-shi, Osaka
Local Institution - 0353, Hidaka-shi, Saitama
Local Institution - 0256, Kitaadachi-gun, Saitama
Local Institution - 0151, Sunto-gun, Shizuoka
Local Institution - 0147, Chuo-ku, Tokyo
Local Institution - 0149, Koto-ku, Tokyo
Local Institution - 0278, Shinjuku-ku, Tokyo
Local Institution - 0157, Wakayama-shi, Wakayama
Local Institution - 0354, Ube-shi, Yamaguchi
Local Institution - 0260, Chiba, Not set
Local Institution - 0165, Okayama, Not set
Local Institution - 0162, Tokyo, Not set
Local Institution - 0136, Seongnam-si, Kyǒnggi-do
Local Institution - 0249, Cheongju-si, Not set
Local Institution - 0133, Gangnam-gu, Not set
Local Institution - 0132, Seoul, Not set
Local Institution - 0135, Seoul, Not set
Local Institution - 0287, Beirut, Not set
Local Institution - 0286, Beirut, Not set
Local Institution - 0196, Df, Distrito Federal
Local Institution - 0193, Mexico, Distrito Federal
Local Institution - 0198, Cuautitlan, Estado DE Mexico
Local Institution - 0197, Guadalajara, Jalisco
Local Institution - 0191, Zapopan, Jalisco
Local Institution - 0267, Morelia, Michoacan
Local Institution - 0277, Monterrey, Nuevo Leon
Local Institution - 0303, Merida, Yucatán
Local Institution - 0192, Chihuahua, Not set
Local Institution - 0195, San Luis Potosi, Not set
Local Institution - 0236, San Luis Potosi, Not set
Local Institution - 0194, Toluca, Not set
Local Institution - 0036, Amsterdam, Not set
Local Institution - 0189, Amsterdam, Not set
Local Institution - 0169, Breda, Not set
Local Institution - 0037, Rotterdam, Not set
Local Institution - 0039, Veldhoven, Not set
Local Institution - 0262, Lima, Not set
Local Institution - 0263, Lima, Not set
Local Institution - 0350, Lima, Not set
Local Institution - 0261, Lima, Not set
Local Institution - 0351, Lima, Not set
Local Institution - 0060, Bydgoszcz, Not set
Local Institution - 0058, Gdansk, Not set
Local Institution - 0063, Gdynia, Not set
Local Institution - 0072, Gliwice, Not set
Local Institution - 0057, Lodz, Not set
Local Institution - 0059, Warszawa, Not set
Local Institution - 0070, Wroclaw, Not set
Local Institution - 0167, Craiova, Not set
Local Institution - 0250, Floresti, Not set
Local Institution - 0166, Romania, Not set
Local Institution - 0284, Sector 2, Not set
Local Institution - 0137, Chelyabinsk, Not set
Local Institution - 0142, Kazan, Not set
Local Institution - 0022, Moscow, Not set
Local Institution - 0049, Saint-Petersburg, Not set
Local Institution - 0028, St. Petersburg, Not set
Local Institution - 0027, St. Petersburg, Not set
Local Institution - 0143, Ufa, Not set
Local Institution - 0264, Pretoria, Gauteng
Local Institution - 0234, Sandton, Gauteng
Local Institution - 0233, Saxonwold, Johannesburg, Gauteng
Local Institution - 0305, Vereeniging, Not set
Local Institution - 0064, Majadahonda, Madrid
Local Institution - 0066, Barcelona, Not set
Local Institution - 0067, Barcelona, Not set
Local Institution - 0065, Madrid, Not set
Local Institution - 0069, Sevilla, Not set
Local Institution - 0068, Valencia, Not set
Local Institution - 0243, Basel, Not set
Local Institution - 0246, Chur, Not set
Local Institution - 0244, Lausanne, Not set
Local Institution - 0245, Winterthur, Not set
Local Institution - 0139, Taichung, Not set
Local Institution - 0138, Taipei, Not set
Local Institution - 0140, Taipei, Not set
Local Institution - 0310, Taipei, Not set
Local Institution - 0141, Taoyuan city, Not set
Local Institution - 0266, Middlesborough, Cleveland
Local Institution - 0098, London, Greater London
Local Institution - 0099, Southampton, Hampshire
Local Institution - 0118, Leicester, Leicestershire
Local Institution - 0265, Birmingham, Not set
Local Institution - 0051, Cambridgeshire, Not set
Local Institution - 0109, Edinburgh, Not set
Local Institution - 0097, London, Not set
Local Institution - 0050, London, Not set
Local Institution - 0119, Surrey, Not set
Conditions: Non-Small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Active Not Recruiting
This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery \[neoadjuvant phase\], followed by pembrolizumab alone after surgery \[adjuvant phase\] in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in combination with NAC, followed by surgery and adjuv... Read More
This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery \[neoadjuvant phase\], followed by pembrolizumab alone after surgery \[adjuvant phase\] in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in combination with NAC, followed by surgery and adjuvant pembrolizumab (vs. placebo) will improve: 1) event free survival (EFS) by biopsy assessed by local pathologist or by investigator-assessed imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); and 2) overall survival (OS). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Banner MD Anderson Cancer Center ( Site 0028), Gilbert, Arizona +226 locations
Banner MD Anderson Cancer Center ( Site 0028), Gilbert, Arizona
Western Regional Medical Center, Inc. ( Site 0050), Goodyear, Arizona
University of Arizona Cancer Center - Dignity Health ( Site 0062), Phoenix, Arizona
University of Arizona Cancer Center ( Site 0012), Tucson, Arizona
Pacific Cancer Medical Center, Inc. ( Site 0004), Anaheim, California
Providence Saint Joseph Medical Center ( Site 0061), Burbank, California
Pacific Cancer Care ( Site 0035), Monterey, California
John Wayne Cancer Institute ( Site 0049), Santa Monica, California
St Joseph Heritage Healthcare ( Site 0040), Santa Rosa, California
Stanford University, Stanford Cancer Center ( Site 0046), Stanford, California
Hartford Hospital ( Site 0069), Hartford, Connecticut
Helen F. Graham Cancer Center & Research Institute ( Site 0015), Newark, Delaware
Mayo Clinic Jacksonville ( Site 0022), Jacksonville, Florida
Miami Cancer Institute-Baptist Hospital ( Site 0068), Miami, Florida
Southeastern Regional Medical Center ( Site 0051), Newnan, Georgia
Northwest Oncology and Hematology ( Site 0001), Elk Grove Village, Illinois
Ingalls Memorial Hospital ( Site 0044), Harvey, Illinois
PPG-Oncology ( Site 0043), Fort Wayne, Indiana
University of Iowa Hospital and Clinics ( Site 0010), Iowa City, Iowa
Ashland-Bellefonte Cancer Center ( Site 0021), Ashland, Kentucky
Harry & Jeanette Weinberg Cancer Institute ( Site 0081), Baltimore, Maryland
Boston Medical Center ( Site 0057), Boston, Massachusetts
UMass Memorial Medical Center ( Site 0030), Worcester, Massachusetts
Henry Ford Health System ( Site 0031), Detroit, Michigan
Herbert Herman Cancer Center, Sparrow Hospital ( Site 0034), Lansing, Michigan
Mayo Clinic ( Site 0026), Rochester, Minnesota
St. Vincent Healthcare Frontier Cancer Center ( Site 0005), Billings, Montana
University of Nebraska Medical Center ( Site 0047), Omaha, Nebraska
Memorial Sloan Kettering Cancer Center Basking Ridge ( Site 0074), Basking Ridge, New Jersey
Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0077), Middletown, New Jersey
MSKCC-Bergen ( Site 0075), Montvale, New Jersey
St. Peter's Hospital Cancer Care Center ( Site 0039), Albany, New York
Montefiore Einstein Center ( Site 0016), Bronx, New York
Memorial Sloan-Kettering Cancer Center at Commack ( Site 0076), Commack, New York
Memorial Sloan Kettering Cancer Center Westchester ( Site 0079), Harrison, New York
Memorial Sloan Kettering Cancer Center ( Site 0060), New York, New York
Stony Brook University Medical Center - Cancer Center ( Site 0019), Stony Brook, New York
Memorial Sloan Kettering Cancer Center - Nassau ( Site 0078), Uniondale, New York
White Plains Hospital Center for Cancer Care ( Site 0007), White Plains, New York
Southwestern Regional Medical Center, Inc. ( Site 0054), Tulsa, Oklahoma
OHSU Center for Health & Healing ( Site 1006), Portland, Oregon
UPMC Pinnacle Health System - East Location ( Site 0063), Harrisburg, Pennsylvania
Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0053), Philadelphia, Pennsylvania
Allegheny General Hospital ( Site 0009), Pittsburgh, Pennsylvania
UPMC Hillman Cancer Centers ( Site 0041), Pittsburgh, Pennsylvania
VA Pittsburgh Healthcare System ( Site 0052), Pittsburgh, Pennsylvania
Saint Francis Cancer Center ( Site 0096), Greenville, South Carolina
Emily Couric Clinical Cancer Center ( Site 0013), Charlottesville, Virginia
Inova Schar Cancer Institute ( Site 0032), Fairfax, Virginia
Virginia Cancer Specialists, PC ( Site 0080), Fairfax, Virginia
Providence Regional Cancer Partnership ( Site 0065), Everett, Washington
Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 0136), Berazategui, Buenos Aires
Hospital Privado de Comunidad. ( Site 0130), Mar del Plata, Buenos Aires
Hospital Universitario Austral ( Site 0127), Pilar, Buenos Aires
Fundacion Favaloro ( Site 0128), Ciudad de Buenos Aires, Caba
Sanatorio Britanico ( Site 0125), Rosario, Santa Fe
Sanatorio Parque ( Site 0135), Rosario, Santa Fe
Hospital Provincial del Centenario ( Site 0131), Rosario, Santa Fe
Hospital Privado Universitario de Córdoba ( Site 0139), Cordoba, Not set
Sanatorio Allende ( Site 0129), Cordoba, Not set
CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica ( Site 0133), San Juan, Not set
Orange Health Services ( Site 0624), Orange, New South Wales
Westmead Hospital ( Site 0621), Westmead, New South Wales
AZ Sint-Maarten ( Site 0226), Mechelen, Antwerpen
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman ( Site 0223), Liège, Liege
UZ Gent ( Site 0224), Gent, Oost-Vlaanderen
AZ Nikolaas ( Site 0225), Sint-Niklaas, Oost-Vlaanderen
UZ Leuven ( Site 0221), Leuven, Vlaams-Brabant
AZ Delta ( Site 0222), Roeselare, West-Vlaanderen
Centro Regional Integrado de Oncologia ( Site 0160), Fortaleza, Ceara
Instituto do Cancer do Ceara ( Site 0152), Fortaleza, Ceara
Sirio-Libanes Brasilia - Centro de Oncologia - Asa Sul ( Site 0159), Brasilia, Distrito Federal
Liga Norte Riograndense Contra o Cancer ( Site 0150), Natal, Rio Grande Do Norte
Hospital de Caridade de Ijui ( Site 0153), Ijui, Rio Grande Do Sul
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0146), Porto Alegre, Rio Grande Do Sul
Hospital Nossa Senhora da Conceicao ( Site 0145), Porto Alegre, Rio Grande Do Sul
YNOVA Pesquisa Clinica ( Site 0823), Florianopolis, Santa Catarina
Fundacao Pio XII - Hospital de Cancer de Barretos ( Site 0144), Barretos, Sao Paulo
Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0149), Rio de Janeiro, Not set
Hospital Paulistano - Amil Clinical Research ( Site 0822), Sao Paulo, Not set
Hospital Alemao Oswaldo Cruz ( Site 0158), Sao Paulo, Not set
Princess Margaret Cancer Centre ( Site 0109), Toronto, Ontario
CIUSSS du Saguenay-Lac-St-Jean ( Site 0101), Chicoutimi, Quebec
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0110), Montreal, Quebec
CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0104), Montreal, Quebec
McGill University Health Centre ( Site 0111), Montreal, Quebec
Tianjin Medical University General Hospital ( Site 0806), Tianjin, Anhui
Beijing Cancer Hospital ( Site 0810), Beijing, Beijing
Beijing Cancer Hospital ( Site 0811), Beijing, Beijing
Cancer Hospital Chinese Academy of Medical Sciences ( Site 0801), Beijing, Beijing
Peking University Third Hospital ( Site 0812), Beijing, Beijing
Peking Union Medical College Hospital ( Site 0809), Beijing, Beijing
Sun Yat-Sen University Cancer Center ( Site 0816), Guangzhou, Guangdong
Hunan Cancer Hospital ( Site 0815), Changsha, Hunan
Fudan University Shanghai Cancer Center ( Site 0813), Shanghai, Shanghai
Zhongshan Hospital of Fudan University ( Site 0808), Shanghai, Shanghai
Shanghai Pulmonary Hospital-Thoracic Surgery department ( Site 0817), Shanghai, Shanghai
Tang Du Hospital ( Site 0803), XI An, Shanxi
The First Affiliated Hospital of Zhejiang University ( Site 0804), Hangzhou, Zhejiang
Zhejiang Cancer Hospital.... ( Site 0814), Hangzhou, Zhejiang
Hwa Mei Hospital University of Chinese Academy of Sciences ( Site 0802), Ningbo, Zhejiang
SA Pohja-Eesti Regionaalhaigla ( Site 1100), Tallinn, Harjumaa
Hopital Foch ( Site 0243), Suresnes, Ain
Nouvel Hopital Civil ( Site 0255), Strasbourg, Bas-Rhin
CHU de Toulouse - Hopital Larrey ( Site 0258), Toulouse, Haute-Garonne
Clinique Francois Chenieux ( Site 0246), Limoges, Haute-Vienne
Hospices Civils de Lyon Centre Hospitalier Lyon Sud ( Site 0241), Pierre-Benite, Rhone-Alpes
Centre Hospitalier Metropole Savoie Site de Chambery ( Site 0245), Chambery, Savoie
Centre Hospitalier Annecy Genevois ( Site 0242), Pringy, Savoie
CHU de Rouen ( Site 0252), Rouen, Seine-Maritime
Hôpital Avicenne - Service d oncologie medicale ( Site 0249), Bobigny, Seine-Saint-Denis
H.I.A. Sainte-Anne ( Site 0251), Toulon, Var
Institut Curie ( Site 0250), Paris, Not set
Klinikum Esslingen GmbH ( Site 0875), Esslingen, Baden-Wurttemberg
LKI Lungenfachklinik Immenhausen ( Site 0268), Immenhausen, Hessen
Florence Nightingale Krankenhaus ( Site 0874), Duesseldorf, Nordrhein-Westfalen
Lungenklinik Hemer ( Site 0269), Hemer, Nordrhein-Westfalen
Mathias Spital Rheine ( Site 0261), Rheine, Nordrhein-Westfalen
Katholisches Klinikum Koblenz Haus Marienhof ( Site 0873), Koblenz, Rheinland-Pfalz
Universitaetsklinikum Carl Gustav Carus ( Site 0273), Dresden, Sachsen
Universitaetsklinikum Leipzig AOeR ( Site 0277), Leipzig, Sachsen
LungenClinic Grosshansdorf GmbH ( Site 0267), Grosshansdorf, Schleswig-Holstein
Universitaetsklinikum Schleswig Holstein ( Site 0871), Kiel, Schleswig-Holstein
Zentralklinik Bad Berka GmbH ( Site 0264), Bad Berka, Thuringen
SRH Waldklinikum Gera GmbH ( Site 0272), Gera, Thuringen
Evangelische Lungenklinik Berlin ( Site 0274), Berlin, Not set
HELIOS Klinikum Emil von Behring ( Site 0280), Berlin, Not set
Asklepios Klinikum Hamburg ( Site 0271), Hamburg, Not set
Cork University Hospital ( Site 0452), Wilton, Cork
St James Hospital ( Site 0451), Dublin, Not set
Mid Western Cancer Centre ( Site 0450), Limerick, Not set
Istituto Nazionale Tumori ( Site 0309), Milano, Abruzzo
Azienda Ospedaliera dei Colli V. Monaldi ( Site 0301), Napoli, Campania
IRST-Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori ( Site 0300), Meldola, Forli-Cesena
Istituto Clinico Humanitas Research Hospital ( Site 0314), Rozzano, Lombardia
ASST Grande Ospedale Metropolitano Niguarda-Oncologia Falck ( Site 0315), Milan, Milano
Azienda Ospedaliera San Gerardo ( Site 0308), Monza, Monza E Brianza
AOU San Luigi Gonzaga di Orbassano ( Site 0313), Orbassano, Torino
Azienda Ospedaliera Spedali Civili di Brescia ( Site 0307), Brescia, Not set
IRCCS Ospedale San Raffaele di Milano ( Site 0303), Milano, Not set
Azienda Ospedaliera San Camillo Forlanini ( Site 0311), Roma, Not set
Aichi Cancer Center Hospital ( Site 0765), Nagoya, Aichi
National Cancer Center Hospital East ( Site 0761), Kashiwa, Chiba
HP of the Univ. of Occupational and Environmental Health, Japan ( Site 0770), Kitakyushu, Fukuoka
Hyogo Cancer Center ( Site 0764), Akashi, Hyogo
St. Marianna University School of Medicine Hospital ( Site 0769), Kawasaki, Kanagawa
Kanagawa Cancer Center ( Site 0763), Yokohama, Kanagawa
Oita University Hospital ( Site 0766), Yufu, Oita
Fukushima Medical University Hospital ( Site 0772), Fukushima, Not set
Hiroshima University Hospital ( Site 0762), Hiroshima, Not set
National Cancer Center Hospital ( Site 0767), Tokyo, Not set
Juntendo University Hospital ( Site 0768), Tokyo, Not set
Tokyo Medical University Hospital ( Site 0771), Tokyo, Not set
National Cancer Center ( Site 0702), Gyeonggi-do, Kyonggi-do
The Catholic University of Korea St. Vincent s Hospital ( Site 0705), Gyeonggi-do, Kyonggi-do
Asan Medical Center ( Site 0701), Seoul, Not set
Samsung Medical Center ( Site 0704), Seoul, Not set
SMG-SNU Boramae Medical Center ( Site 0707), Seoul, Not set
Pauls Stradins Clinical University Hospital ( Site 0911), Riga, Not set
Riga East Clinical University Hospital ( Site 0912), Riga, Not set
LSMUL Kauno Klinikos ( Site 0932), Kaunas, Not set
Nacionalinis Vezio Institutas ( Site 0931), Vilnius, Not set
Sarawak General Hospital ( Site 0782), Kuching, Sarawak
University Malaya Medical Centre ( Site 0781), Kuala Lumpur, Not set
Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 0484), Bystra, Dolnoslaskie
Dolnoslaskie Centrum Onkologii. ( Site 0491), Wroclaw, Dolnoslaskie
Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 0488), Bydgoszcz, Kujawsko-pomorskie
Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi ( Site 0493), Lodz, Lodzkie
Szpital Specjalistyczny w Prabutach Sp. z o.o. ( Site 0483), Prabuty, Pomorskie
Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 0487), Poznan, Wielkopolskie
S C Pelican Impex SRL ( Site 0506), Oradea, Bihor
Centrul Medical Medicover Victoria ( Site 0514), Bucharest, Bucuresti
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0501), Cluj Napoca, Cluj
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0515), Cluj-Napoca, Cluj
SC Radiotherapy Center Cluj SRL ( Site 0509), Comuna Floresti, Cluj
S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0504), Craiova, Dolj
S.C.R.T.C.Radiology Therapeutic Center SRL ( Site 0511), Otopeni, Ilfov
S C Oncocenter Oncologie Medicala S R L ( Site 0505), Timisoara, Timis
Spitalul Sf. Constantin ( Site 0512), Brasov, Not set
Euroclinic Hospital Bucharest ( Site 0510), Bucuresti, Not set
S.C.Focus Lab Plus S.R.L ( Site 0513), Bucuresti, Not set
Spitalul clinic Judetean de urgenta Constanta ( Site 0508), Constanta, Not set
Spitalul Judetean de Urgenta .Sf. Ioan cel Nou. ( Site 0503), Suceava, Not set
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 0530), Chelyabinsk, Chelyabinskaya Oblast
N.N. Blokhin NMRCO ( Site 0521), Moscow, Moskva
National Medical Research Radiology Centre ( Site 0535), Moscow, Moskva
Medical Rehabilitation Center ( Site 0534), Moscow, Moskva
SBHI Leningrad Regional Clinical Hospital ( Site 0524), Saint Petersburg, Sankt-Peterburg
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0533), Saint Petersburg, Sankt-Peterburg
Municipal Clinical Oncology Center ( Site 0523), Saint Petersburg, Sankt-Peterburg
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 0529), Kazan, Tatarstan, Respublika
Tomsk Scientific Research Institute of Oncology ( Site 0526), Tomsk, Tomskaya Oblast
Wits Clinical Research ( Site 0570), Parktown-Johannesburg, Gauteng
Wilgers Oncology Centre ( Site 0573), Pretoria, Gauteng
The Oncology Centre ( Site 0571), Durban, Kwazulu-Natal
Cape Town Oncology Trials Pty Ltd ( Site 0572), Kraaifontein, Western Cape
Hospital Germans Trias i Pujol. ICO de Badalona ( Site 0381), Badalona, Barcelona
Instituto Catalan de Oncologia - ICO ( Site 0388), L Hospitalet De Llobregat, Barcelona
Hospital Universitario de Girona Doctor Josep Trueta ( Site 0386), Girona, La Coruna
Hospital Universitario Insular de Gran Canaria ( Site 0383), Las Palmas de Gran Canaria, Las Palmas
Hospital de la Santa Creu i Sant Pau ( Site 0385), Barcelona, Not set
Hospital Universitari Vall d Hebron ( Site 0389), Barcelona, Not set
Hospital General Universitario Gregorio Maranon ( Site 0382), Madrid, Not set
Hospital Virgen del Rocio ( Site 0387), Sevilla, Not set
Kaohsiung Chang Gung Memorial Hospital ( Site 0725), Kaohsiung, Not set
China Medical University Hospital ( Site 0724), Taichung, Not set
National Taiwan University Hospital ( Site 0721), Taipei, Not set
Taipei Veterans General Hospital ( Site 0722), Taipei, Not set
Tri-Service General Hospital ( Site 0726), Taipei, Not set
Chang Gung Medical Foundation.Linkou Branch ( Site 0723), Taoyuan, Not set
Cherkassy Regional Oncological Center ( Site 0613), Cherkasy, Cherkaska Oblast
City Clinical Hosp.4 of DCC ( Site 0607), Dnipro, Dnipropetrovska Oblast
MI Precarpathian Clinical Oncology Center ( Site 0603), Ivano-Frankivsk, Ivano-Frankivska Oblast
MI KhRC Kherson Regional Oncology Dispensary ( Site 0614), Kherson, Khersonska Oblast
PP PPC Acinus Medical and Diagnostic Centre ( Site 0609), Kropyvnytsky, Kirovohradska Oblast
National Cancer Institute of the MoH of Ukraine ( Site 0605), Kyiv, Kyivska Oblast
Kyiv City Clinical Oncological Center ( Site 0601), Kyiv, Kyivska Oblast
MI Odessa Regional Oncological Centre ( Site 0608), Odesa, Odeska Oblast
Zaporizhzhya Regional Clinical Oncology Center ( Site 0606), Zaporizhzhya, Zaporizka Oblast
Leicester Royal Infirmary ( Site 0447), Leicester, Leicestershire
The Clatterbridge Cancer Centre NHS Foundation Trust ( Site 0456), Wirral, Liverpool
Royal Marsden NHS Foundation Trust ( Site 0458), London, London, City Of
Royal Marsden Hospital ( Site 0457), Sutton, London, City Of
Nottingham City Hospital Campus ( Site 0441), Nottingham, Nottinghamshire
Heartlands Hospital in Birmingham ( Site 0455), Birmingham, Not set
Freeman Hospital ( Site 0444), Newcastle upon Tyne, Not set
Plymouth Hospitals NHS Trust ( Site 0443), Plymouth, Not set
Conditions: Non-small Cell Lung Cancer
97 - 108 of 298